INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI 2005–2010

RC-Specific Evaluation of CompDisGen – Complex Disease Genomics Group

Seppo Saari & Antti Moilanen (Eds.)
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI 2005–2010

RC-Specific Evaluation of CompDisGen – Complex Disease Genomics Group

Seppo Saari & Antti Moilanen (Eds.)
Summary:
Researcher Community (RC) was a new concept of the participating unit in the evaluation. Participation in the evaluation was voluntary and the RCs had to choose one of the five characteristic categories to participate.

Evaluation of the Researcher Community was based on the answers to the evaluation questions. In addition a list of publications and other activities were provided by the TUHAT system. The CWTS/Leiden University conducted analyses for 80 RCs and the Helsinki University Library for 66 RCs. Panellists, 49 and two special experts in five panels evaluated all the evaluation material as a whole and discussed the feedback for RC-specific reports in the panel meetings in Helsinki. The main part of this report is consisted of the feedback which is published as such in the report.

Chapters in the report:
1. Background for the evaluation
2. Evaluation feedback for the Researcher Community
3. List of publications
4. List of activities
5. Bibliometric analyses

The level of the RCs' success can be concluded from the written feedback together with the numeric evaluation of four evaluation questions and the category fitness. More conclusions of the success can be drawn based on the University-level report.

RC-specific information:

Main scientific field of research: Medicine, Biomedicine and Health Sciences

Participation category:
1. Research of the participating community represents the international cutting edge in its field

RC's responsible person:
Kaprio, Jaakko

RC-specific keywords:
gene, mutation, genetics, genomics, linkage, association, disease, complex trait, pedigree, human, dog, mouse, cardiovascular disease, autoimmune disease, migraine, epilepsy, psychiatric disease, asthma, dyslexia, hypertension, obesity, metabolic disorder, substance abuse disorder, copy number variation, mapping, GWAS, SNP, polymorphic, linear regression, comparative genetics, animal model, bioinformatics, systems biology, meta-analysis

Keywords:
Research Evaluation, Meta-evaluation, Doctoral Training, Bibliometric Analyses, Researcher Community
Contents

Panel members .................................................................................................................................. 1

1 Introduction to the Evaluation .................................................................................................... 5
  1.1 RC-specific evaluation reports ............................................................................................ 5
  1.2 Aims and objectives in the evaluation ................................................................................. 5
  1.3 Evaluation method ............................................................................................................... 5
  1.4 Implementation of the external evaluation ....................................................................... 6
  1.5 Evaluation material ............................................................................................................. 7
  1.6 Evaluation questions and material .................................................................................... 8
  1.7 Evaluation criteria .............................................................................................................. 10
  1.8 Timetable of the evaluation ............................................................................................... 13
  1.9 Evaluation feedback – consensus of the entire panel ....................................................... 13

2 Evaluation feedback .................................................................................................................. 15
  2.1 Focus and quality of the RC’s research .............................................................................. 15
  2.2 Practises and quality of doctoral training ......................................................................... 15
  2.3 The societal impact of research and doctoral training ...................................................... 16
  2.4 International and national (incl. intersectoral) research collaboration and researcher mobility ... 16
  2.5 Operational conditions ....................................................................................................... 16
  2.6 Leadership and management in the researcher community ............................................ 17
  2.7 External competitive funding of the RC .......................................................................... 17
  2.8 The RC’s strategic action plan for 2011–2013 .................................................................. 18
  2.9 Evaluation of the category of the RC in the context of entity of the evaluation material (1-8) ... 18
  2.10 Short description of how the RC members contributed the compilation of the stage 2 material ... 18
  2.11 How the UH’s focus areas are presented in the RC’s research ........................................ 18
  2.12 RC-specific main recommendations ................................................................................ 18
  2.13 RC-specific conclusions .................................................................................................. 18
  2.14 Preliminary findings in the Panel-specific feedback ......................................................... 19
  2.15 Preliminary findings in the University-level evaluation ................................................... 20

3 Appendices .................................................................................................................................. 21
Foreword

The evaluation of research and doctoral training is being carried out in the years 2010–2012 and will end in 2012. The steering group appointed by the Rector in January 2010 set the conditions for participating in the evaluation and prepared the Terms of Reference to present the evaluation procedure and criteria. The publications and other scientific activities included in the evaluation covered the years 2005–2010.

The participating unit in the evaluation was defined as a Researcher Community (RC). To obtain a critical mass with university-level impact, the number of members was set to range from 20 to 120. The RCs were required to contain researchers in all stages of their research career, from doctoral students to principal investigators (PIs). All in all, 136 Researcher Communities participated in this voluntary evaluation, 5857 persons in total, of whom 1131 were principal investigators. PIs were allowed to participate in two communities in certain cases, and 72 of them used this opportunity and participated in two RCs.

This evaluation enabled researchers to define RCs from the “bottom up” and across disciplines. The aim of the evaluation was not to assess individual performance but a community with shared aims and researcher-training activities. The RCs were able to choose among five different categories that characterised the status and main aims of their research. The steering group considered the process of applying to participate in the evaluation to be important, which lead to the establishment of these categories. In addition, providing a service for the RCs to enable them to benchmark their research at the global level was a main goal of the evaluation.

The data for the evaluation consisted of the RCs’ answers to evaluation questions on supplied e-forms and a compilation extracted from the TUHAT – Research Information System (RIS) on 12 April 2011. The compilation covered scientific and other publications as well as certain areas of scientific activities. During the process, the RCs were asked to check the list of publications and other scientific activities and make corrections if needed. These TUHAT compilations are public and available on the evaluation project sites of each RC in the TUHAT-RIS.

In addition to the e-form and TUHAT compilation, University of Leiden (CWTS) carried out bibliometric analyses from the articles included in the Web of Science (WoS). This was done on University and RC levels. In cases where the publication forums of the RC were clearly not represented by the WoS data, the Library of the University of Helsinki conducted a separate analysis of the publications. This was done for 66 RCs representing the humanities and social sciences.

The evaluation office also carried out an enquiry targeted to the supervisors and PhD candidates about the organisation of doctoral studies at the University of Helsinki. This and other documents describing the University and the Finnish higher education system were provided to the panellists.

The panel feedback for each RC is unique and presented as an entity. The first collective evaluation reports available for the whole panel were prepared in July–August 2011. The reports were accessible to all panel members via the electronic evaluation platform in August. Scoring from 1 to 5 was used to complement written feedback in association with evaluation questions 1–4 (scientific focus and quality, doctoral training, societal impact, cooperation) and in addition to the category evaluating the fitness for participation in the evaluation. Panellists used the international level as a point of comparison in the evaluation. Scoring was not expected to go along with a preset deviation.

Each of the draft reports were discussed and dealt with by the panel in meetings in Helsinki (from 11 September to 13 September or from 18 September to 20 September 2011). In these meetings the panels also examined the deviations among the scores and finalised the draft reports together.

The current RC-specific report deals shortly with the background of the evaluation and the terms of participation. The main evaluation feedback is provided in the evaluation report, organised according to the evaluation questions. The original material provided by the RCs for the panellists has been attached to these documents.
On behalf of the evaluation steering group and office, I sincerely wish to thank you warmly for your participation in this evaluation. The effort you made in submitting the data to TUHAT-RIS is gratefully acknowledged by the University. We wish that you find this panel feedback useful in many ways. The bibliometric profiles may open a new view on your publication forums and provide a perspective for discussion on your choice of forums. We especially hope that this evaluation report will help you in setting the future goals of your research.

Johanna Björkroth
Vice-Rector
Chair of the Steering Group of the Evaluation

Steering Group of the evaluation
Steering group, nominated by the Rector of the University, was responsible for the planning of the evaluation and its implementation having altogether 22 meetings between February 2010 and March 2012.

Chair
Vice-Rector, professor Johanna Björkroth

Vice-Chair
Professor Marja Airaksinen
Chief Information Specialist, Dr Maria Forsman
Professor Arto Mustajoki
University Lecturer, Dr Kirsi Pyhälö
Director of Strategic Planning and Development, Dr Ossi Tuomi
Doctoral candidate, MSocSc Jussi Vauhkonen
Panel members

CHAIR
Professor Lorenz Poellinger
Cancer biology, cell and molecular biology
Karolinska Institute, Sweden

VICE-CHAIR
Professor Cornelia van Duijn
Genetic epidemiology, Alzheimer’s disease and related disorders
Erasmus Medical Centre, the Netherlands

Professor Johanna Ivaska
Molecular cell biology, cell adhesion, cancer biology
University of Turku, VTT Technical Research Centre, Finland

Professor Olli Lassila
Immunology, medical microbiology
University of Turku, Finland

Professor Hans-Christian Pape
Neuroscience, neurophysiology
University of Münster, Germany

Professor Thomas Ruzicka
Dermatology, allergology
Ludwig-Maximilians-Universität (LMU) München, Germany

Professor Lars Terenius
Experimental alcohol and drug dependence research, mental disorders, preventive medicine
Karolinska Institute, Sweden

Professor Peter York
Physical pharmaceutics, pharmaceutical chemistry, pharmaceutical technology
University of Bradford, Great Britain

The panel, independently, evaluated all the submitted material and was responsible for the feedback of the RC-specific reports. The panel members were asked to confirm whether they had any conflict of interests with the RCs. If this was the case, the panel members disqualified themselves in discussion and report writing.

Added expertise to the evaluation was contributed by two evaluators outside the panels and by three members from the other panels.

External Experts
Professor Olli Carpén
Pathology, cancer cell metastasis
University of Turku
Finland

Professor Anders Linde
Oral biochemistry
Faculty of Odontology
Göteborg University
Sweden
Experts from the Other Panels
Professor Jan-Otto Carlsson, from the Panel of Natural Sciences
Professor Danny Huylebroek, from the Panel of Biological, Agricultural and Veterinary Sciences
Professor Holger Stark, from the Panel of Natural Sciences

EVALUATION OFFICE
Dr Seppo Saari, Doc., Senior Adviser in Evaluation, was responsible for the entire evaluation, its planning and implementation and acted as an Editor-in-chief of the reports.
Dr Eeva Sievi, Doc., Adviser, was responsible for the registration and evaluation material compilations for the panellists. She worked in the evaluation office from August 2010 to July 2011.
MSocSc Paula Ranne, Planning Officer, was responsible for organising the panel meetings and all the other practical issues like agreements and fees and editing a part the RC-specific reports. She worked in the evaluation office from March 2011 to January 2012.
Mr Antti Möllanen, Project Secretary, was responsible for editing the reports. He worked in the evaluation office from January 2012 to April 2012.

TUHAT OFFICE
Provision of the publication and other scientific activity data
Mrs Aija Kaitera, Project Manager of TUHAT-RIS served the project ex officio providing the evaluation project with the updated information from TUHAT-RIS. The TUHAT office assisted in mapping the publications with CWTS/University of Leiden.
MA Liisa Ekebom, Assisting Officer, served in TUHAT-RIS updating the publications for the evaluation. She also assisted the UH/Library analyses.
BA Liisa Jäppinen, Assisting Officer, served in TUHAT-RIS updating the publications for the evaluation.

HELSINKI UNIVERSITY LIBRARY
Provision of the publication analyses
Dr Maria Forsman, Chief Information Specialist in the Helsinki University Library, managed with her 10 colleagues the bibliometric analyses in humanities, social sciences and in other fields of sciences where CWTS analyses were not applicable.
Acronyms and abbreviations applied in the report

External competitive funding
AF – Academy of Finland
TEKES - Finnish Funding Agency for Technology and Innovation
EU - European Union
ERC - European Research Council
International and national foundations
FP7/6 etc. /Framework Programmes/Funding of European Commission

Evaluation marks
Outstanding (5)
Excellent (4)
Very Good (3)
Good (2)
Sufficient (1)

Abbreviations of Bibliometric Indicators
P - Number of publications
TCS – Total number of citations
MCS - Number of citations per publication, excluding self-citations
PNC - Percentage of uncited publications
MNCS - Field-normalized number of citations per publication
MNJS - Field-normalized average journal impact
THCP10 - Field-normalized proportion highly cited publications (top 10%)
INT_COV - Internal coverage, the average amount of references covered by the WoS
WoS – Thomson Reuters Web of Science Databases

Participation category
Category 1. The research of the participating community represents the international cutting edge in its field.
Category 2. The research of the participating community is of high quality, but the community in its present composition has yet to achieve strong international recognition or a clear break-through.
Category 3. The research of the participating community is distinct from mainstream research, and the special features of the research tradition in the field must be considered in the evaluation.
Category 4. The research of the participating community represents an innovative opening.
Category 5. The research of the participating community has a highly significant societal impact.

Research focus areas of the University of Helsinki
Focus area 1: The basic structure, materials and natural resources of the physical world
Focus area 2: The basic structure of life
Focus area 3: The changing environment – clean water
Focus area 4: The thinking and learning human being
Focus area 5: Welfare and safety
Focus area 6: Clinical research
Focus area 7: Precise reasoning
Focus area 8: Language and culture
Focus area 9: Social justice
Focus area 10: Globalisation and social change
1 Introduction to the Evaluation

1.1 RC-specific evaluation reports

The participants in the evaluation of research and doctoral training were Researcher Communities (hereafter referred to as the RC). The RC refers to the group of researchers who registered together in the evaluation of their research and doctoral training. Preconditions in forming RCs were stated in the Guidelines for the Participating Researcher Communities. The RCs defined themselves whether their compositions should be considered well-established or new.

It is essential to emphasise that the evaluation combines both meta-evaluation and traditional research assessment exercise and its focus is both on the research outcomes and procedures associated with research and doctoral training. The approach to the evaluation is enhancement-led where self-evaluation constituted the main information. The answers to the evaluation questions formed together with the information of publications and other scientific activities an entity that was to be reviewed as a whole.

The present evaluation recognizes and justifies the diversity of research practices and publication traditions. Traditional Research Assessment Exercises do not necessarily value high quality research with low volumes or research distinct from mainstream research. It is challenging to expose the diversity of research to fair comparison. To understand the essence of different research practices and to do justice to their diversity was one of the main challenges of the present evaluation method. Understanding the divergent starting points of the RCs demanded sensitivity from the evaluators.

1.2 Aims and objectives in the evaluation

The aims of the evaluation are as follows:

- to improve the level of research and doctoral training at the University of Helsinki and to raise their international profile in accordance with the University’s strategic policies. The improvement of doctoral training should be compared to the University’s policy.
- to enhance the research conducted at the University by taking into account the diversity, originality, multidisciplinary nature, success and field-specificity,
- to recognize the conditions and prerequisites under which excellent, original and high-impact research is carried out,
- to offer the academic community the opportunity to receive topical and versatile international peer feedback,
- to better recognize the University’s research potential.
- to exploit the University’s TUHAT research information system to enable transparency of publishing activities and in the production of reliable, comparable data.

1.3 Evaluation method

The evaluation can be considered as an enhancement-led evaluation. Instead of ranking, the main aim is to provide useful information for the enhancement of research and doctoral training of the participating RCs. The comparison should take into account each field of science and acknowledge their special character.

---

1 The panellists did not read research reports or abstracts but instead, they evaluated answers to the evaluation questions, tables and compilations of publications, other scientific activities, bibliometrics or comparable analyses.

2 Policies on doctoral degrees and other postgraduate degrees at the University of Helsinki.
The comparison produced information about the present status and factors that have lead to success. Also challenges in the operations and outcomes were recognized.

The evaluation approach has been designed to recognize better the significance and specific nature of researcher communities and research areas in the multidisciplinary top-level university. Furthermore, one of the aims of the evaluation is to bring to light those evaluation aspects that differ from the prevalent ones. Thus the views of various fields of research can be described and research arising from various starting points understood better. The doctoral training is integrated into the evaluation as a natural component related to research. Operational processes of doctoral training are being examined in the evaluation.

Five stages of the evaluation method were:
1. Registration – Stage 1
2. Self-evaluation – Stage 2
3. TUHAT\(^3\) compilations on publications and other scientific activities\(^4\)
4. External evaluation
5. Public reporting

1.4 Implementation of the external evaluation

Five Evaluation Panels
Five evaluation panels consisted of independent, renowned and highly respected experts. The main domains of the panels are:
1. biological, agricultural and veterinary sciences
2. medicine, biomedicine and health sciences
3. natural sciences
4. humanities
5. social sciences

The University invited 10 renowned scientists to act as chairs or vice-chairs of the five panels based on the suggestions of faculties and independent institutes. Besides leading the work of the panel, an additional role of the chairs was to discuss with other panel chairs in order to adopt a broadly similar approach. The panel chairs and vice-chairs had a pre-meeting on 27 May 2011 in Amsterdam.

The panel compositions were nominated by the Rector of the University 27 April 2011. The participating RCs suggested the panel members. The total number of panel members was 50. The reason for a smaller number of panellists as compared to the previous evaluations was the character of the evaluation as a meta-evaluation. The panellists did not read research reports or abstracts but instead, they evaluated answers to the evaluation questions, tables and compilations of publications, other scientific activities, bibliometrics and comparable analyses.

The panel meetings were held in Helsinki:
- On 11–13 September 2011: (1) biological, agricultural and veterinary sciences, (2) medicine, biomedicine and health sciences and (3) natural sciences.
- On 18–20 September 2011: (4) humanities and (5) social sciences.

---

\(^3\) TUHAT (acronym) of Research Information System (RIS) of the University of Helsinki

\(^4\) Supervision of thesis, prizes and awards, editorial work and peer reviews, participation in committees, boards and networks and public appearances.
1.5 Evaluation material

The main material in the evaluation was the RCs' self-evaluations that were qualitative in character and allowed the RCs to choose what was important to mention or emphasise and what was left unmentioned.

The present evaluation is exceptional at least in the Finnish context because it is based on both the evaluation documentation (self-evaluation questions, publications and other scientific activities) and the bibliometric reports. All documents were delivered to the panellists for examination.

Traditional bibliometrics can be reasonably done mainly in medicine, biosciences and natural sciences when using the Web of Science database, for example. Bibliometrics, provided by CWTS/The Centre for Science and Technology Studies, University of Leiden, cover only the publications that include WoS identification in the TUHAT-RIS.

Traditional bibliometrics are seldom relevant in humanities and social sciences because the international comparable databases do not store every type of high quality research publications, such as books and monographs and scientific journals in other languages than English. The Helsinki University Library has done analysis to the RCs, if their publications were not well represented in the Web of Science databases (RCs should have at least 50 publications and internal coverage of publications more than 40%) – it meant 58 RCs. The bibliometric material for the evaluation panels was available in June 2011. The RC-specific bibliometric reports are attached at the end of each report.

The panels were provided with the evaluation material and all other necessary background information, such as the basic information about the University of Helsinki and the Finnish higher education system.

Evaluation material
1. Registration documents of the RCs for the background information
2. Self evaluation material – answers to the evaluation questions
3. Publications and other scientific activities based on the TUHAT RIS:
   3.1. statistics of publications
   3.2. list of publications
   3.3. statistics of other scientific activities
   3.4. list of other scientific activities
4. Bibliometrics and comparable analyses:
   4.1. Analyses of publications based on the verification of TUHAT-RIS publications with the Web of Science publications (CWTS/University of Leiden)
   4.2. Publication statistics analysed by the Helsinki University Library - mainly for humanities and social sciences
5. University level survey on doctoral training (August 2011)
6. University level analysis on publications 2005–2010 (August 2011) provided by CWTS/University of Leiden

Background material

University of Helsinki
- Basic information about the University of the Helsinki
- The structure of doctoral training at the University of Helsinki
- Previous evaluations of research at the University of Helsinki – links to the reports: 1998 and 2005

The Finnish Universities/Research Institutes
- Finnish University system
- Evaluation of the Finnish National Innovation System
- The State and Quality of Scientific Research in Finland. Publication of the Academy of Finland 9/09.

The evaluation panels were provided also with other relevant material on request before the meetings in Helsinki.
1.6 Evaluation questions and material

The participating RCs answered the following evaluation questions which are presented according to the evaluation form. In addition, TUHAT RIS was used to provide the additional material as explained. For giving the feedback to the RCs, the panellists received the evaluation feedback form constructed in line with the evaluation questions:

1. Focus and quality of the RC’s research
   - Description of
     - the RC’s research focus.
     - the quality of the RC’s research (incl. key research questions and results)
     - the scientific significance of the RC’s research in the research field(s)
   - Identification of the ways to strengthen the focus and improve the quality of the RC’s research

The additional material: TUHAT compilation of the RC’s publications, analysis of the RC’s publications data (provided by University of Leiden and the Helsinki University Library)
A written feedback from the aspects of: scientific quality, scientific significance, societal impact, innovativeness
   - Strengths
   - Areas of development
   - Other remarks
   - Recommendations

Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1)

2. Practises and quality of doctoral training
   - Organising of the doctoral training in the RC. Description of the RC’s principles for:
     - recruitment and selection of doctoral candidates
     - supervision of doctoral candidates
     - collaboration with faculties, departments/institutes, and potential graduate schools/docoral programmes
     - good practises and quality assurance in doctoral training
   - Identification of the ways to strengthen the practises and quality of doctoral training, and the actions planned for their development.

The additional material: TUHAT compilation of the RC’s other scientific activities/supervision of doctoral dissertations
A written feedback from the aspects of: processes and good practices related to leadership and management
   - Strengths
   - Areas of development
   - Other remarks
   - Recommendations

Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1)

3. The societal impact of research and doctoral training
   - Description on how the RC interacts with and contributes to the society (collaboration with public, private and/or 3rd sector).
   - Identification of the ways to strengthen the societal impact of the RC’s research and doctoral training.

The additional material: TUHAT compilation of the RC’s other scientific activities.
A written feedback from the aspects of: societal impact, national and international collaboration, innovativeness
   - Strengths
   - Areas of development
   - Other remarks
   - Recommendations

Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1)
4. **International and national (incl. intersectoral) research collaboration and researcher mobility**
   - Description of
     - the RC’s research collaborations and joint doctoral training activities
     - how the RC has promoted researcher mobility
   - Identification of the RC’s strengths and challenges related to research collaboration and researcher mobility, and the actions planned for their development.
   
   A written feedback from the aspects of: scientific quality, national and international collaboration
   - Strengths
   - Areas of development
   - Other remarks
   - Recommendations

   **Numeric evaluation:** OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1)

5. **Operational conditions**
   - Description of the operational conditions in the RC’s research environment (e.g. research infrastructure, balance between research and teaching duties).
   - Identification of the RC’s strengths and challenges related to operational conditions, and the actions planned for their development.
   
   A written feedback from the aspects of: processes and good practices related to leadership and management
   - Strengths
   - Areas of development
   - Other remarks
   - Recommendations

6. **Leadership and management in the researcher community**
   - Description of
     - the execution and processes of leadership in the RC
     - how the management-related responsibilities and roles are distributed in the RC
     - how the leadership- and management-related processes support
       - high quality research
       - collaboration between principal investigators and other researchers in the RC
       - the RC’s research focus
       - strengthening of the RC’s know-how
   - Identification of the RC’s strengths and challenges related to leadership and management, and the actions planned for developing the processes

7. **External competitive funding of the RC**
   - The RCs were asked to provide information of such external competitive funding, where:
     - the funding decisions have been made during 1.1.2005-31.12.2010, and
     - the administrator of the funding is/has been the University of Helsinki
   - On the e-form the RCs were asked to provide:
     1) The relevant funding source(s) from a given list (Academy of Finland/Research Council, TEKES/The Finnish Funding Agency for Technology and Innovation, EU, ERC, foundations, other national funding organisations, other international funding organisations), and
     2) The total sum of funding which the organisation in question had decided to allocate to the RCs members during 1.1.2005–31.12.2010.
   
   Competitive funding reported in the text is also to be considered when evaluating this point.
   
   A written feedback from the aspects of: scientific quality, scientific significance, societal impact, innovativeness, future significance
   - Strengths
   - Areas of development
   - Other remarks
   - Recommendations

8. **The RC’s strategic action plan for 2011-2013**
   - RC’s description of their future perspectives in relation to research and doctoral training.
   
   A written feedback from the aspects of: scientific quality, scientific significance, societal impact, processes and good practices related to leadership and management, national and international collaboration, innovativeness, future significance
   - Strengths
   - Areas of development
9. Evaluation of the category of the RC in the context of entity of the evaluation material (1-8)

The RC’s fitness to the chosen participation category
A written feedback evaluating the RC’s fitness to the chosen participation category

- Strengths
- Areas of development
- Other remarks
- Recommendations

Numeric evaluation: OUTSTANDING (5), EXCELLENT (4), VERY GOOD (3), GOOD (2), SUFFICIENT (1)

10. Short description of how the RC members contributed the compilation of the stage 2 material

Comments on the compilation of evaluation material

11. How the UH’s focus areas are presented in the RC’s research?

Comments if applicable

12. RC-specific main recommendations based on the previous questions 1-11

13. RC-specific conclusions

1.7 Evaluation criteria

The panellists were expected to give evaluative and analytical feedback to each evaluation question according to their aspects in order to describe and justify the quality of the submitted material. In addition, the evaluation feedback was asked to be pointed out the level of the performance according to the following classifications:

- outstanding (5)
- excellent (4)
- very good (3)
- good (2)
- sufficient (1)

Evaluation according to the criteria was to be made with thorough consideration of the entire evaluation material of the RC in question. Finally, in questions 1-4 and 9, the panellists were expected to classify their written feedback into one of the provided levels (the levels included respective descriptions, ‘criteria’). Some panels used decimals in marks. The descriptive level was interpreted according to the integers and not rounding up the decimals by the editors.

Description of criteria levels

Question 1 – FOCUS AND QUALITY OF THE RC’S RESEARCH

Classification: Criteria (level of procedures and results)

Outstanding quality of procedures and results (5)

Outstandingly strong research, also from international perspective. Attracts great international interest with a wide impact, including publications in leading journals and/or monographs published by leading international publishing houses. The research has world leading qualities. The research focus, key research questions scientific significance, societal impact and innovativeness are of outstanding quality.

In cases where the research is of a national character and, in the judgement of the evaluators, should remain so, the concepts of “international attention” or “international impact” etc. in the grading criteria above may be replaced by “international comparability”.

Other remarks
Recommendations
Operations and procedures are of outstanding quality, transparent and shared in the community. The improvement of research and other efforts are documented and operations and practices are in alignment with the documentation. The ambition to develop the community together is of outstanding quality.

**Excellent quality of procedures and results (4)**

Research of excellent quality. Typically published with great impact, also internationally. Without doubt, the research has a leading position in its field in Finland.

Operations and procedures are of excellent quality, transparent and shared in the community. The improvement of research and other efforts are documented and operations and practices are to large extent in alignment with the documentation. The ambition to develop the community together is of excellent quality.

**Very good quality of procedures and results (3)**

The research is of such very good quality that it attracts wide national and international attention.

Operations and procedures are of very good quality, transparent and shared in the community. The improvement of research and other efforts are documented and operations and practices are to large extent in alignment with the documentation. The ambition to develop the community together is of very good quality.

**Good quality of procedures and results (2)**

Good research attracting mainly national attention but possessing international potential, extraordinarily high relevance may motivate good research.

Operations and procedures are of good quality, shared occasionally in the community. The improvement of research and other efforts are occasionally documented and operations and practices are to large extent in alignment with the documentation. The ambition to develop the community together is of good quality.

**Sufficient quality of procedures and results (1)**

In some cases the research is insufficient and reports do not gain wide circulation or do not have national or international attention. Research activities should be revised.

Operations and procedures are of sufficient quality, shared occasionally in the community. The improvement of research and other efforts are occasionally documented and operations and practices are to some extent in alignment with the documentation. The ambition to develop the community together is of sufficient quality.

**Question 2 – DOCTORAL TRAINING**

**Question 3 – SOCIETAL IMPACT**

**Question 4 – COLLABORATION**

**Classification: Criteria (level of procedures and results)**

**Outstanding quality of procedures and results (5)**

Procedures are of outstanding quality, transparent and shared in the community. The practices and quality of doctoral training/societal impact/international and national collaboration/leadership and management are documented and operations and practices are in alignment with the documentation. The ambition to develop the community together is of outstanding quality. The procedures and results are regularly evaluated and the feedback has an effect on the planning.

**Excellent quality of procedures and results (4)**

Procedures are of excellent quality, transparent and shared in the community. The practices and quality of doctoral training/societal impact/international and national collaboration/leadership and management are documented and operations and practices are to large extent in alignment with the documentation. The ambition to develop the community together is of excellent quality. The procedures and outcomes are evaluated and the feedback has an effect on the planning.

**Very good quality of procedures and results (3)**

Procedures are of very good quality, transparent and shared in the community. The practices and quality of doctoral training/societal impact/international and national collaboration/leadership and
management are documented and operations and practices are to large extent in alignment with the documentation. The ambition to develop the community together is of very good quality.

**Good quality of procedures and results (2)**

Procedures are of good quality, shared occasionally in the community. The practices and quality of doctoral training/societal impact/international and national collaboration/leadership and management are documented and operations and practices are to large extent in alignment with the documentation. The ambition to develop the community together is of good quality.

**Sufficient quality of procedures and results (1)**

Procedures are of sufficient quality, transparent and shared in the community. The practices and quality of doctoral training/societal impact/international and national collaboration/leadership and management are occasionally documented and operations and practices are to some extent in alignment with the documentation. The ambition to develop the community together is of sufficient quality.

**Question 9 – CATEGORY**

Participation category – fitness for the category chosen

The choice and justification for the chosen category below should be reflected in the RC’s responses to the evaluation questions 1–8.

1. *The research of the participating community represents the international cutting edge in its field.*

2. *The research of the participating community is of high quality, but the community in its present composition has yet to achieve strong international recognition or a clear break-through.*

3. *The research of the participating community is distinct from mainstream research, and the special features of the research tradition in the field must be considered in the evaluation.* The research is of high quality and has great significance and impact in its field. However, the generally used research evaluation methods do not necessarily shed sufficient light on the merits of the research.

4. *The research of the participating community represents an innovative opening.* A new opening can be an innovative combination of research fields, or it can be proven to have a special social, national or international demand or other significance. Even if the researcher community in its present composition has yet to obtain proof of international success, its members can produce convincing evidence of the high level of their previous research.

5. *The research of the participating community has a highly significant societal impact.* The participating researcher community is able to justify the high social significance of its research. The research may relate to national legislation, media visibility or participation in social debate, or other activities promoting social development and human welfare. In addition to having societal impact, the research must be of a high standard.

**An example of outstanding fitness for category choice (5)**

The RC’s representation and argumentation for the chosen category were convincing. The RC recognized its real capacity and apparent outcomes in a wider context to the research communities. The specific character of the RC was well-recognized and well stated in the responses. The RC fitted optimally for the category.

- Outstanding (5)
- Excellent (4)
- Very good (3)
- Good (2)
- Sufficient (1)

The above-mentioned definition of outstanding was only an example in order to assist the panellists in the positioning of the classification. There was no exact definition for the category fitness.

---

5 The panels discussed the category fitness and made the final conclusions of the interpretation of it.
1.8 Timetable of the evaluation

The main timetable of the evaluation:

1. Registration  November 2010
3. External peer review  May–September 2011
4. Published reports  March–April 2012
   - University level public report
   - RC specific reports

The entire evaluation was implemented during the university’s strategy period 2010–2012. The preliminary results were available for the planning of the following strategy period in late autumn 2011. The evaluation reports will be published in March/April 2012. More detailed time schedule is published in the University report.

1.9 Evaluation feedback – consensus of the entire panel

The panellists evaluated all the RC-specific material before the meetings in Helsinki and mailed the draft reports to the evaluation office. The latest interim versions were on-line available to all the panellists on the Wiki-sites. In September 2011, in Helsinki the panels discussed the material, revised the first draft reports and decided the final numeric evaluation. After the meetings in Helsinki, the panels continued working and finalised the reports before the end of November 2011. The final RC-specific reports are the consensus of the entire panel.

The evaluation reports were written by the panels independently. During the editing process, the evaluation office requested some clarifications from the panels when necessary. The tone and style in the reports were not harmonized in the editing process. All the reports follow the original texts written by the panels as far as it was possible.

The original evaluation material of the RCs, provided for the panellists is attached at the end of the report. It is essential to notice that the exported lists of publications and other scientific activities depend how the data was stored in the TUHAT-RIS by the RCs.
2 Evaluation feedback

2.1 Focus and quality of the RC’s research

- Description of
  - the RC’s research focus
  - the quality of the RC’s research (incl. key research questions and results)
  - the scientific significance of the RC’s research in the research field(s)
- Identification of the ways to strengthen the focus and improve the quality of the RC’s research

ASPECTS: Scientific quality, scientific significance, societal impact, innovativeness

The RC covers a broad area of research in human disease genetics including studies of the Finnish Disease Heritage with several monogenic disorders unique to Finland. General complex traits have been the major focus over the past five years. The RC has participated actively in the wave of genome wide associations (GWA). Without a doubt, the RC had many successes in the past decade. A major strength of the group has been the implementation of new technology into clinical and epidemiological research. As to the research area of focus, there is a wide interest. This is strength in terms of participating in many genetic studies and being part of many high profile papers. However, the other side of the coin is that the group is not always recognized as leading in a field of subject matter. A question to the RC is whether it would be important to define a distinct set of research lines of interest targeting specific disorders (lipids, metabolic syndrome?) or risk factors (smoking?) that will be flagships for the group and will give the group high profile/leadership. From the Leiden literature-analyses, metabolism and endocrinology have yielded the largest volume of papers.

The output of the group has been extremely high including over almost a 1000 articles many in the highest-impact journals across biomedical and clinical science in 2005-2010 including at least 12 Nature papers, 44 Nature Genetics papers, 3 in Science, 9 together in NEJM and Lancet, 15 in PlosGenet and 24 in AJHG. The average H-index of the group is 31.6. The RC is extremely active in various international consortia.

Numeric evaluation: 5 (Outstanding)

2.2 Practises and quality of doctoral training

- Organising of the doctoral training in the RC. Description of the RC’s principles for:
  - recruitment and selection of doctoral candidates
  - supervision of doctoral candidates
  - collaboration with faculties, departments/institutes, and potential graduate schools/doctoral programmes
  - good practises and quality assurance in doctoral training
  - assuring of good career perspectives for the doctoral candidates/fresh doctorates
- Identification of the RC’s strengths and challenges related to the practises and quality of doctoral training, and the actions planned for their development.
- Additional material: TUHAT compilation of the RC’s other scientific activities/supervision of doctoral dissertations

ASPECTS: Processes and good practices related to leadership and management

Currently in the RC, there are 34 PhD students enrolled. There are over 100 Doctoral theses. Seventeen RC members have acted as supervisors during 2005-2010. Group leaders have all been involved in several graduate schools. The courses and tutoring of graduate schools in the University of Helsinki have provided the skeleton for the training of the researchers within the RC. Each graduate student has a thesis
committee with scientists outside the RC. One of the strength of the RC is that it integrates basic science (molecular genetics) with clinical science (clinical genetics) and epidemiology (particular genomic epidemiology and biostatistics). There is a large market for the PhD’s for jobs in and outside Finland. The RC has an international perspective.

Numeric evaluation: 5 (Outstanding)

2.3 The societal impact of research and doctoral training

- Description on how the RC interacts with and contributes to the society (collaboration with public, private and/or 3rd sector).
- Identification of the ways to strengthen the societal impact of the RC’s research and doctoral training.
- Additional material: TUHAT compilation of the RC’s other scientific activities.

ASPECTS: Societal impact, national and international collaboration, innovativeness

The group has had a high visibility in Europe and the rest of the world, which was mostly driven by the late Leena Peltonen. The network of the group is large and spans major institutes in Europe (Welcome, Karolinska) and the US (Broad). In the short term, the links will be maintained. The long term perspective is less clear at this point, and the RC should outline a strategy to maintain the high level for the future. The major societal/public impact has been in the field of the Finnish diseases. These findings were translated successfully into public health and clinical practice. The translation of findings on complex disease or behavioral factors (smoking) to the community will be a more difficult challenge.

Numeric evaluation: 5 (Outstanding)

2.4 International and national (incl. intersectoral) research collaboration and researcher mobility

- Description of
  - the RC’s research collaborations and joint doctoral training activities
  - how the RC has promoted researcher mobility
- Identification of the RC’s strengths and challenges related to research collaboration and researcher mobility, and the actions planned for their development.

ASPECTS: Scientific quality, national and international collaboration

One of the hallmarks of this RC is its strong partnership with major international research centers. Members of the RC have faculty positions in the Karolinska Institute in Sweden, the Broad Institute in the United States and the Sanger Institute in the United Kingdom. These partnerships facilitate key roles in large international pioneering projects. Such current projects include the 1000genomes project and the UK10K project (www.uk10k.org). The mobility of the RC is high at all levels (senior, junior, postdoc).

Numeric evaluation: 5 (Outstanding)

2.5 Operational conditions

- Description of the operational conditions in the RC’s research environment (e.g. research infrastructure, balance between research and teaching duties).
- Identification of the RC’s strengths and challenges related to operational conditions, and the actions planned for their development.

ASPECTS: Processes and good practices related to leadership and management
The infrastructure is excellent both for complex diseases and typical Finnish diseases. The strength of the RC is at present the combination of large epidemiological studies and clinical series with technology. Their new target is next generation sequencing which is ongoing now. The RC benefits from an up-to-date technology center such as FIMM. For large scale computations and statistics also the Centre for Scientific Computing is highly relevant. There is not a strong plan worked out for future plans beyond high-throughput sequencing.

2.6 Leadership and management in the researcher community

- Description of
  - the execution and processes of leadership in the RC
  - how the management-related responsibilities and roles are distributed in the RC
  - how the leadership- and management-related processes support
    - high quality research
    - collaboration between principal investigators and other researchers in the RC
    - the RC’s research focus
    - strengthening of the RC’s know-how
- Identification of the RC’s strengths and challenges related to leadership and management, and the actions planned for developing the processes

ASPECTS: Processes and good practices related to leadership and management

The management structure seems to be flat and orientated towards PI’s, institutes (e.g. FIMM) and collaborations. The collaboration among principal investigators is excellent. This requires some elucidation. It is not clear to the panel how the tragic loss of Leena Peltonen will be compensated in terms of leadership in genetics. It will be difficult if not impossible to replace, but in the coming years, it will be important to develop a strategy to maintain the quality of research and maintain the know-how. A key issue to consider is whether there is a need to define a research focus that will give the group a recognizable profile in which they are recognized as experts in Europe and the world.

2.7 External competitive funding of the RC

- The RCs were asked to provide information of such external competitive funding, where:
  - the funding decisions have been made during 1.1.2005–31.12.2010, and
  - the administrator of the funding is/has been the University of Helsinki
- On the e-form the RCs were asked to provide:
  1) The relevant funding source(s) from a given list (Academy of Finland/Research Council, TEKES/The Finnish Funding Agency for Technology and Innovation, EU, ERC, foundations, other national funding organisations, other international funding organizations), and
  2) The total sum of funding which the organisation in question had decided to allocate to the RCs members during 1.1.2005–31.12.2010.

Competitive funding reported in the text is also to be considered when evaluating this point.

ASPECTS: Scientific quality, scientific significance, societal impact, innovativeness and future significance

There is a high degree of competitive funding. Funding includes the Academy of Finland, TEKES, ERC, Solhberg Foundation, Finnish Cultural Foundation, Gastroenterology foundation, Pesatu, Nurmi Foundation, Finnish Foundation for Cardiovascular Research, Wallenberg Foundation, European Science Foundation, Novo Nordisk Fonden, KELA, Pfizer Foundation, Sigrid Juselius Foundation, NIH, Karolinska institutet, AKC Canine Foundation, Swedish Research Council, NordForsk, CIMO, Uppsala University, Indiana University and EVO, HUSLAB, Biocentrum Helsinki, University of Helsinki Funds, University of Helsinki, National Institute for Health and Welfare (THL), Ministry of Education and Culture, Helsinki
2.8 The RC’s strategic action plan for 2011–2013

- RC’s description of their future perspectives in relation to research and doctoral training.

ASPECTS: Scientific quality, scientific significance, societal impact, processes and good practices related to leadership and management, national and international collaboration, innovativeness, future significance

Basically, the RC proposes to continue the work on complex diseases, moving from GWAS to high throughput sequencing. It is the obvious step, but there is little detail. It is not clear where they will put the cards: which outcomes, disease or behavior factors, which populations, and who will be responsible for what. There is little view in the document on priorities and goals for the group or for the individual members.

2.9 Evaluation of the category of the RC in the context of entity of the evaluation material (1-8)

The RC’s fitness to the chosen participation category.

Category 1. The research of the participating community represents the international cutting edge in its field.

There is no doubt that achievements, publications and infrastructure justify the category outstanding.

Numeric evaluation: 5 (Outstanding)

2.10 Short description of how the RC members contributed the compilation of the stage 2 material

-

2.11 How the UH’s focus areas are presented in the RC’s research

Focus area 2: The basic structure of life

-

2.12 RC-specific main recommendations

The major request of the panel is develop more structure: both in management as well key topics to address in the near future. This is particular relevant now that one of the key leaders deceased sadly.

2.13 RC-specific conclusions

The RC is without a doubt competitive in its category 1. The infrastructure developed over the years gives the group an extremely good head start. In the coming year, there is a need to develop a strategical plan.
for future research, outlining areas of focus. Another important task will be the development of a research management structure that will guaranty competitiveness.

2.14 Preliminary findings in the Panel-specific feedback

See questions above.

The RC covers a broad area of research in human disease genetics including studies of the Finnish Disease Heritage with several monogenic disorders unique to Finland. General complex traits have been the major focus over the past five years. The RC has participated actively in the wave of genome wide associations (GWA). Without doubt, the RC had many successes the past decade. A major strength of the group has been the implementation of new technology into clinical and epidemiological research. As to the research area of focus, there is a wide interest. This is strength in terms of participating in many genetic studies and being part of many high profile papers. However, the other side of the coin is that the group is not always recognized as leading in a field of subject matter. A question to the RC is whether it would be important to define a distinct set of research lines of interest targeting specific disorders (lipids, metabolic syndrome?) or risk factors (smoking?) that will be flagships for the group and will give the group high profile/leadership. From the Leiden literature-analyses metabolism and endocrinology have yielded the largest volume of papers.

The output of the group has been extremely high including over almost a 1000 articles many in the highest-impact journals across biomedical and clinical science in 2005-2010 including at least 12 Nature papers, 44 Nature Genetics papers, 3 in Science, 9 together in NEJM and Lancet, 15 in PlosGenet and 24 in AJHG. The average H-index of the group is 31.6. The RC is extremely active in various international consortia. There are over 100 Doctoral theses. RC members have acted as supervisors during 2005-2010. Group leaders have all been involved in several graduate schools. The courses and tutoring of graduate schools in the University of Helsinki have provided the skeleton for the training of the researchers within the RC. Each graduate student has a thesis committee with scientists outside the RC. One of the strength of the RC is that it integrates basic science (molecular genetics) with clinical science (clinical genetics) and epidemiology (particular genomic epidemiology and biostatistics). There is a large market for the PhDs for jobs in and outside Finland. The RC has an international perspective.

The group has had a high visibility in Europe and the world, which was mostly driven by the late Leena Peltonen. The network of the group is large spans major institutes in the Europe (Welcome, Karolinska) and the US (Broad). In the short term, the links will be maintained. The long term perspective is less clear at this point in the absence of Leena Peltonen, asking the RC to outline a strategy to maintain the high level for the future. The major societal/public impact has been in the field of the Finnish diseases. These findings were translated successfully into public health and clinical practice. The translation of findings on complex disease or behavioral factors (smoking) to the community will be a more difficult challenge. Collaboration with private interests is primarily technology driven.

One of the hallmarks of this RC is its strong partnership with major international research centers. Members of the RC have faculty positions in the Karolinska Institute in Sweden, the Broad Institute in the United States and the Sanger Institute in the United Kingdom. These partnerships facilitate key roles in large international pioneering projects. Such current projects include the 1000genomes project and the UK10K project (www.uk10k.org). The mobility of the RC is high at all levels (senior, junior, postdoc). The infrastructure is excellent both for complex diseases and typical Finnish diseases. The strength of the RC is at present the combination of large epidemiological studies and clinical series with technology. Their new target is next generation sequencing which is ongoing now. The RC benefits from an up to date technology center such as FIMM. For large scale computations and statistics also the Centre for Scientific Computing is highly relevant. There is not a strong plan worked out for future plans beyond high-throughput sequencing.

The collaboration among principal investigators is excellent. The management structure seems to be flat and orientated towards PI’s and institutes (e.g. FIMM) and collaborations. This requires some elucidation. It is not clear to the committee how the tragic loss of Leena Peltonen will be compensated in terms of leadership in genetics. It will be difficult if not impossible to replace but in the coming years it will
be important to develop a strategy to maintain the quality of research and maintain the know-how. A key issue to consider is whether there is a need to define a research focus that will give the group a recognizable profile in which they are recognized as experts in Europe and the world. Up until now, there is excellent external funding.

2.15 Preliminary findings in the University-level evaluation

The RC covers a broad area of research in human disease genetics including studies of the Finnish Disease Heritage with several monogenic disorders unique to Finland. General complex traits have been the major focus over the past five years. The RC has participated actively in the wave of genome wide associations (GWA). Without a doubt, the RC had many successes the past decade. The output of the group has been extremely high including over almost a 1000 articles many in the highest-impact journals across biomedical and clinical science in 2005-2010 including at least 12 Nature papers, 44 Nature Genetics papers, 3 in Science, 9 together in NEJM and Lancet, 15 in PlosGenet and 24 in AJHG. The average H-index of the group is 31.6. The RC is extremely active in various international consortia. A major strength of the group has been the implementation of new technology into clinical and epidemiological research. As to the research area focus, there is a wide interest. This is strength in terms of participating in many genetic studies and being part of many high profile papers. However, the other side of the coin is that the group is not always recognized as leading in a field of subject matter. A question to the RC is whether it would be important to define a distinct set of research lines of interest targeting specific disorder that will be flagships for the group and will give the group high profile/leadership.

One of the strength of the RC is that it integrates basic science (molecular genetics) with clinical science (clinical genetics) and epidemiology (particular genomic epidemiology and biostatistics). There is a large market for the PhDs for jobs in and outside Finland. The RC has an international perspective. The group has had a high visibility in Europe and the world, which was mostly driven by the late Leena Peltonen. The network of the group is large spans major institutes in the Europe (Welcome, Karolinska) and the US (Broad). In the short term, the links will be maintained. One of the hallmarks of this RC is its strong partnership with major international research centers. Members of the RC have faculty positions in the Karolinska Institute in Sweden, the Broad Institute in the United States and the Sanger Institute in the United Kingdom. These partnerships facilitate key roles in large international pioneering projects. Such current projects include the 1000Genomes project and the UK10K project (www.uk10k.org). The mobility of the RC is high at all levels (senior, junior, postdoc). The infrastructure is excellent both for complex diseases and typical Finnish diseases. The long term perspective is less clear at this point in the absence of Leena Peltonen, asking the RC to outline a strategy to maintain the high level for the future. The major societal/public impact has been in the field of the Finnish diseases. These findings were translated successfully into public health and clinical practice. The translation of findings on complex disease or behavioral factors (smoking) to the community will be a more difficult challenge. Collaboration with the private interests is primarily technology driven.

The strength of the RC is at present the combination of large epidemiological studies and clinical series with technology. The collaboration among principal investigators is excellent. The management structure seems to flat and orientated towards PIs and institutes. This raises question for the future. It is not clear to the committee how the tragic loss of Leena Peltonen will be compensated in terms of leadership in genetics. In the coming years it will be important to develop a strategy to maintain the quality of research and maintain the know-how. A key issue to consider is whether there is a need to define a research focus that will give the group a recognizable profile in which they are recognized as experts in Europe and the world. Up until now, there is excellent external funding.
3 Appendices

A. Original evaluation material
   a. Registration material – Stage 1
   b. Answers to evaluation questions – Stage 2
   c. List of publications
   d. List of other scientific activities

B. Bibliometric analyses
   a. Analysis provided by CWTS/University of Leiden
   b. Analysis provided by Helsinki University Library (66 RCs)
NAME OF THE RESEARCHER COMMUNITY:
Complex Disease Genomics Group (CompDisGen)

LEADER OF THE RESEARCHER COMMUNITY:
Professor Jaakko Kaprio, Department of Public Health, University of Helsinki; Institute for Molecular Medicine Finland (FIMM)

RC-SPECIFIC MATERIAL FOR THE PEER REVIEW:
- Material submitted by the RC at stages 1 and 2 of the evaluation
  - STAGE 1 material: RC's registration form (incl. list of RC participants in an excel table)
  - STAGE 2 material: RC's answers to evaluation questions
- TUHAT compilations of the RC members' other scientific activities 1.1.2005-31.12.2010
  (analysis carried out by CWTS, Leiden University)

NB! Since Web of Science(WoS)-based bibliometrics does not provide representative results for most RCs representing humanities, social sciences and computer sciences, the publications of these RCs will be analyzed by the UH Library (results available by the end of June, 2011)
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC STAGE 1 MATERIAL (registration form)

---

**1 RESPONSIBLE PERSON**

Name: Kaprio, Jaakko

E-mail: 

Phone: +358 9 191 27 595

Affiliation: Professor of Genetic Epidemiology

Street address: Mannerheimintie 172

---

**2 DESCRIPTION OF THE PARTICIPATING RESEARCHER COMMUNITY (RC)**

Name of the participating RC (max. 30 characters): Complex Disease Genomics Group

Acronym for the participating RC (max. 10 characters): CompDisGen

Description of the operational basis in 2005-2010 (eg. research collaboration, joint doctoral training activities) on which the RC was formed (MAX. 2200 characters with spaces): The RC integrates the strengths of Finnish molecular genetics, clinical science, genomic epidemiology and biostatistics. The PIs of the RC include scientists with a worldwide-recognized expertise and a strong track record in respective fields. Many of the PIs belong to the Academy of Finland Center of Excellence in Complex Disease Genetics. They have also made a significant contribution to doctoral training at the University. The RC has participated actively on the wave of genome wide associations (GWA), which has been a success story in the identification of common variants associated with complex traits over the past 5 years. However, typically these variants explain only a small fraction of the genetic variance of the trait. The missing genetic variance may be accounted for by 1) common variants where the effect size is very small, odds ratios less than 1.1, 2) a large number of relatively rare variants that are responsible for a significant proportion of unidentified genetic predisposition, and 3) gene-environmental interactions. The variants identified in GWA have stimulated research to understand their impact on cellular, individual and population level. Well characterized, large epidemiological Finnish collections provide a special opportunity to study the contribution of individual variants, combination of variants and their cross talk with environmental and life style factors on disease susceptibility at different stages of life. Our RC encompasses a wide range of studies on many complex diseases for which the genetic architecture varies. Our RC has also developed unique animal models such as mice and dogs to further help to identify and model the molecular background and pathogenesis of human inherited diseases. Through active collaborations between the partners in the RC, and with scientists and labs outside the RC at the University of Helsinki as well as with other research groups nationally and internationally, the RC has contributed strongly to new knowledge of the genetic basis of common diseases and their risk factors.

---

**3 SCIENTIFIC FIELDS OF THE RC**

Main scientific field of the RC’s research: medicine, biomedicine and health sciences

RC’s scientific subfield 1: Genetics and Heredity
RC’s scientific subfield 2: Biochemistry and Molecular Biology
RC’s scientific subfield 3: Veterinary Sciences
RC’s scientific subfield 4: --Select--
Other, if not in the list: Comparative Genetics, Epidemiology, Translational Medicine

4 RC’S PARTICIPATION CATEGORY

Participation category: 1. Research of the participating community represents the international cutting edge in its field

Justification for the selected participation category (MAX. 2200 characters with spaces): Our RC has decided to become evaluated in the Category 1. The established RC includes many active and internationally well-recognized and established investigators in the field of human genetics. Our RC has generated tens of new doctorate students and postdocs and has published over 800 articles many in the highest-impact journals across biomedical and clinical science in 2005-2010 including at least 12 Nature papers, 44 Nature Genetics papers, 3 in Science, 9 together in NEJM and Lancet, 15 in PlosGenet and 24 in AJHG. The PIs are highly cited, very productive and successful in generating external grants. Through active collaborations between the partners in the RC, and with scientists and labs outside the RC at the University of Helsinki as well as with other research groups nationally and internationally, the RC has contributed strongly to new knowledge of the genetic basis of common diseases and their risk factors. Our outstanding track record in terms of publications and external grants justifies the Evaluation category 1.

5 DESCRIPTION OF THE RC’S RESEARCH AND DOCTORAL TRAINING

Public description of the RC’s research and doctoral training (MAX. 2200 characters with spaces): Our RC represents a long and well-established tradition in human disease genetics including studies of the Finnish Disease Heritage with several monogenic disorders unique to Finland. Subsequent development of human genetics towards complex traits has been the major focus over the past five years. The RC has participated actively on the wave of genome wide associations (GWA), which has been a success story in the identification of common variants associated with complex traits. The variants identified in GWA have stimulated research to understand their impact on cellular, individual and population level. Well characterized, large epidemiological Finnish collections provide a special opportunity to study the contribution of individual variants, combination of variants and their cross talk with environmental and lifestyle factors on disease susceptibility at different stages of life. Our RC encompasses a wide range of studies on many complex diseases for which the genetic architecture varies. To further study and dissect the molecular mechanisms of various diseases we have also developed several unique animal models of human complex disease including canine genetic system. Through active collaborations between the partners in the RC, and with scientists and labs outside the RC at the University of Helsinki as well as with other research groups nationally and internationally, the RC has contributed strongly to new knowledge of the genetic basis of common diseases and their risk factors. The RC groups have extensive experience in training of graduate students and postdoctoral fellows and the group leaders have all been involved several graduate schools. The courses and tutoring of graduate schools in the University of Helsinki have provided the skeleton for the training of the researchers within the RC. Each graduate student has thesis committee with scientists outside the RC. The RC has trained numerous scientists with 54 PhDs defended at the
University of Helsinki in 2005-2010 and currently there are 34 PhD students enrolled. Seventeen RC members have acted as supervisors during 2005-2010.

**Significance of the RC’s research and doctoral training for the University of Helsinki (MAX. 2200 characters with spaces):** The RC comprises the best expertise overall in complex disease genetics at the University of Helsinki and Finland and is well-recognized worldwide. The research area in human disease genetics is also highly-recognized among the general public according to the Finnish Science Barometer 2010. The RC contains PIs that are internationally prominent scientists including memberships for example in the Nobel committee. ERCStG was awarded to Hannes Lohi in 2010. RC’s expertise spans technologies, epidemiology & sample collection, biobanking, analyses and translational activities including animal models and preclinical trials. The RC plays a key role in the development and maintenance of infrastructure as core facilities needed for the state-of-art genetic and genomic research. An important element is the FIMM Technology Centre, which is a local, national and international infrastructure and service facility developing new technologies and serving the user community with state of the art technologies. FIMM Technology Centre has excellent research facilities, including high- and medium throughput systems for genotyping, sequencing, transcript profiling, high-throughput RNAi screening, and translational technologies. To serve the needs of computation and data management FIMM Technology Centre has tripled its computational processing power and continues to increase its capacity of the storage array network (SAN). FIMM Technology Centre maintains over hundred physical and virtual servers used for hosting bioinformatics databases and other applications. The Centre utilizes the latest IT tools such as virtualization and scale-out storage technologies to provide a robust and scalable platform for doing data intensive science. Collaboration with Centre for Scientific Computing (www.CSC.fi) enables usage of CSC facilities when very high capabilities are needed. Based on the development of this outstanding expertise, infrastructure and reputation the RC has been eminently successful in external grant competitions and in attracting gifted students for PhD studies and postdoctoral work.

**Keywords:** gene, mutation, genetics, genomics, linkage, association, disease, complex trait, pedigree, human, dog, mouse, cardiovascular disease, autoimmune disease, migraine, epilepsy, psychiatric disease, asthma, dyslexia, hypertension, obesity, metabolic disorder, substance abuse disorder, copy number variation, mapping, GWAS, SNP, polymorphic, linear regression, comparative genetics, animal model, bioinformatics, systems biology, meta-analysis

**6 QUALITY OF RC’S RESEARCH AND DOCTORAL TRAINING**

**Justified estimate of the quality of the RC’s research and doctoral training at national and international level during 2005-2010 (MAX. 2200 characters with spaces):** Our research spans national and international collaborations. At the University of Helsinki, we work across faculties and research institutes. The most important ones are FIMM and the Research Programs Unit of the Faculty of Medicine. National collaborations are also close with the National Institute for Health and Welfare, but also with other state research institutes, Finnish Universities and Biocenter Finland. A very productive relationship with the Wellcome Trust Sanger Institute has existed. Many PIs have also international affiliations. One of the largest International studies closely integrated with the RC is the ENGAGE integrated project of the FP7 program of EU for which UH is the lead coordinator. This 12 M€ project focuses on pooling datasets across
over 120,000 GWA studies in traits related to metabolic syndrome, cardiovascular diseases and obesity and characterization of joint actions between genetic profiles and lifestyle. A multi-site NIDA/NCI funding aims to identify functional genes for nicotine dependence on chromosome 22. Newly funded or impending EU FP7 projects that we are involved in include TORNADO (gut microbe – dietary interactions in obesity and metabolic diseases); GENODISC (structural and functional genomics of intervertebral disc degeneration); BioSHARE (Biobank Standardization and Harmonization); SYNSYS (A European Expert Network in Building Synapse). In addition to continuing our collaborations in existing EU projects such as EUROHEAD, DIOGENES, EUROCLOT, GEHA, EPICURE, LUPA (dog genomics) and SGENE. Because of the role of RC investigators in Wellcome Trust Sanger Institute, Broad Institute (Palotie, Peltonen) and Karolinska Institute (Kere) RC investigators participate often in a leading role in large international collaborative efforts. This guarantees excellent access to data produced by projects like Hapmap3, 1000 Genomes and EUVADIS (aiming to sequence 1000 individuals with early disease phenotype in cardiovascular and metabolic diseases). These collaborations also harmonize operations of CoE with critical Nordic operators in biobanking and genetic and disease databases (Nordic Center of Excellence, www.ncoedg.org).

Comments on how the RC’s scientific productivity and doctoral training should be evaluated (MAX. 2200 characters with spaces): Our RC members are basic scientists. We can be evaluated on the basis of our publication record, citations, external grants and significant recognitions in addition to our track record in research training. We can be compared to other groups on a global level, and all research groups in the RC have active networks of collaborations with individual centres in Finland and internationally. Research groups with similar programs and research questions in complex disease genetics include Helmholtz Centre in Munich, DeCode Genetics in Reykjavik, The Broad Institute, Boston, MA, Karolinska Institute, and Framingham Study in Boston, US. Our output has been extremely productive and at the highest scientific level. Many of our PhD students have pursued an active scientific career in post-doc positions in Finland and internationally, with continuing scientific productivity. We publish cutting-edge research in the best possible journals.
<table>
<thead>
<tr>
<th>Last name</th>
<th>First name</th>
<th>PI-status (TUHAT-check, lista 29.11.)</th>
<th>Title of research and teaching personnel</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kaprio</td>
<td>Jaakko</td>
<td>x</td>
<td>Research Director, Professor</td>
<td>Department of Public Health, University of Helsinki and Institute for Molecular Medicine Finland FIMM</td>
</tr>
<tr>
<td>Bogl</td>
<td>Leonie-Helen</td>
<td></td>
<td>Doctoral candidate</td>
<td>Department of Public Health, University of Helsinki</td>
</tr>
<tr>
<td>Broms</td>
<td>Ulla</td>
<td></td>
<td>Doctoral candidate -&gt; Postdoctoral</td>
<td>Department of Public Health, University of Helsinki</td>
</tr>
<tr>
<td>Hukkanen</td>
<td>Marija</td>
<td></td>
<td>Doctoral candidate</td>
<td>Department of Public Health, University of Helsinki</td>
</tr>
<tr>
<td>Keski-Raikkonen</td>
<td>Anna</td>
<td>x</td>
<td>Postdoctoral researcher</td>
<td>Department of Public Health, University of Helsinki</td>
</tr>
<tr>
<td>Korhonen</td>
<td>Tellervo</td>
<td>x</td>
<td>Senior researcher</td>
<td>Department of Public Health, University of Helsinki</td>
</tr>
<tr>
<td>Laajunen</td>
<td>Hanna-Reetta</td>
<td></td>
<td>Doctoral candidate -&gt; Postdoctoral</td>
<td>Department of Public Health, University of Helsinki</td>
</tr>
<tr>
<td>Latvala</td>
<td>Antti</td>
<td></td>
<td>Doctoral candidate</td>
<td>Department of Public Health, University of Helsinki</td>
</tr>
<tr>
<td>Loukola</td>
<td>Aru</td>
<td></td>
<td>University researcher</td>
<td>Department of Public Health, University of Helsinki</td>
</tr>
<tr>
<td>Mustelin</td>
<td>Linda</td>
<td></td>
<td>Doctoral candidate</td>
<td>Department of Public Health, University of Helsinki</td>
</tr>
<tr>
<td>Ollikainen</td>
<td>Miina</td>
<td></td>
<td>Postdoctoral researcher</td>
<td>Department of Public Health, University of Helsinki</td>
</tr>
<tr>
<td>Ortega-Alonso</td>
<td>Alfredo</td>
<td></td>
<td>Postdoctoral researcher</td>
<td>Department of Public Health, University of Helsinki</td>
</tr>
<tr>
<td>Piihitilainen</td>
<td>Kirsu</td>
<td>x</td>
<td>University researcher</td>
<td>Department of Public Health, University of Helsinki and Institute for Molecular Medicine Finland FIMM</td>
</tr>
<tr>
<td>Raanemäki</td>
<td>Aru</td>
<td></td>
<td>Doctoral candidate -&gt; Postdoctoral</td>
<td>Department of Public Health, University of Helsinki</td>
</tr>
<tr>
<td>Saarni</td>
<td>Suoma</td>
<td></td>
<td>Doctoral candidate -&gt; Postdoctoral</td>
<td>Department of Public Health, University of Helsinki</td>
</tr>
<tr>
<td>Sihvola</td>
<td>Elina</td>
<td></td>
<td>Doctoral candidate -&gt; Postdoctoral</td>
<td>Department of Public Health, University of Helsinki and Department of Psychiatry</td>
</tr>
<tr>
<td>Vuokko</td>
<td>Kaisu</td>
<td></td>
<td>Doctoral candidate -&gt; Postdoctoral</td>
<td>Department of Public Health, University of Helsinki</td>
</tr>
<tr>
<td>Kere</td>
<td>Juha</td>
<td>x</td>
<td>Research Director, Professor</td>
<td>Department of Medical Genetics, University of Helsinki</td>
</tr>
<tr>
<td>Etohama</td>
<td>Outi</td>
<td></td>
<td>Senior researcher</td>
<td>Department of Medical Genetics, University of Helsinki</td>
</tr>
<tr>
<td>Hannula-Jouppi</td>
<td>Katarina</td>
<td>x</td>
<td>University researcher</td>
<td>Department of Medical Genetics, University of Helsinki</td>
</tr>
<tr>
<td>Järvinen</td>
<td>Tiina</td>
<td></td>
<td>Doctoral candidate</td>
<td>Department of Medical Genetics, University of Helsinki</td>
</tr>
<tr>
<td>Kaminen-Aholan</td>
<td>Nina</td>
<td></td>
<td>Doctoral candidate</td>
<td>Department of Medical Genetics, University of Helsinki</td>
</tr>
<tr>
<td>Lappalainen</td>
<td>Tuuli</td>
<td></td>
<td>Doctoral candidate</td>
<td>Department of Medical Genetics, University of Helsinki</td>
</tr>
<tr>
<td>Maasinen</td>
<td>Satu</td>
<td></td>
<td>Doctoral candidate</td>
<td>Department of Medical Genetics, University of Helsinki</td>
</tr>
<tr>
<td>Pulkkinnen</td>
<td>Ville</td>
<td></td>
<td>Doctoral candidate -&gt; Postdoctoral</td>
<td>Department of Medical Genetics, University of Helsinki</td>
</tr>
<tr>
<td>Rautanen</td>
<td>Anna</td>
<td></td>
<td>Doctoral candidate</td>
<td>Department of Medical Genetics, University of Helsinki</td>
</tr>
<tr>
<td>Salmenla</td>
<td>Elina</td>
<td></td>
<td>Doctoral candidate</td>
<td>Department of Medical Genetics, University of Helsinki</td>
</tr>
<tr>
<td>Sundman</td>
<td>Lilli</td>
<td></td>
<td>Doctoral candidate</td>
<td>Department of Medical Genetics, University of Helsinki</td>
</tr>
<tr>
<td>Tervaniemoti</td>
<td>Mari</td>
<td></td>
<td>Doctoral candidate</td>
<td>Department of Medical Genetics, University of Helsinki</td>
</tr>
<tr>
<td>Tiaha</td>
<td>Inkeri</td>
<td></td>
<td>Doctoral candidate</td>
<td>Department of Medical Genetics, University of Helsinki</td>
</tr>
<tr>
<td>Versnellin</td>
<td>Johanna</td>
<td></td>
<td>Doctoral candidate -&gt; Postdoctoral</td>
<td>Department of Medical Genetics, University of Helsinki</td>
</tr>
<tr>
<td>Wedenjoja</td>
<td>Satu</td>
<td></td>
<td>Doctoral candidate -&gt; Postdoctoral</td>
<td>Department of Medical Genetics, University of Helsinki</td>
</tr>
<tr>
<td>Kontula</td>
<td>Kimmo</td>
<td>x</td>
<td>Research Director, Professor</td>
<td>Department of Clinical Medicine, University of Helsinki</td>
</tr>
<tr>
<td>Backlund</td>
<td>Mikael</td>
<td></td>
<td>Doctoral candidate</td>
<td>Department of Clinical Medicine, University of Helsinki</td>
</tr>
<tr>
<td>Donner</td>
<td>Kati</td>
<td></td>
<td>Postdoctoral researcher</td>
<td>Department of Clinical Medicine, University of Helsinki</td>
</tr>
<tr>
<td>Hiitonen</td>
<td>Timo</td>
<td></td>
<td>Clinical instructor</td>
<td>Department of Clinical Medicine, University of Helsinki</td>
</tr>
<tr>
<td>Lahtinen</td>
<td>Annukka</td>
<td></td>
<td>Doctoral candidate</td>
<td>Department of Clinical Medicine, University of Helsinki</td>
</tr>
<tr>
<td>Lehtonen</td>
<td>Jukka</td>
<td></td>
<td>Postdoctoral researcher</td>
<td>Department of Clinical Medicine, University of Helsinki</td>
</tr>
<tr>
<td>Marjamaa</td>
<td>Annukka</td>
<td></td>
<td>Doctoral candidate -&gt; Postdoctoral</td>
<td>Department of Clinical Medicine, University of Helsinki</td>
</tr>
<tr>
<td>Paukku</td>
<td>Kirsu</td>
<td></td>
<td>Postdoctoral researcher</td>
<td>Department of Clinical Medicine, University of Helsinki</td>
</tr>
<tr>
<td>Suoninjärvi</td>
<td>Timo</td>
<td></td>
<td>Doctoral candidate</td>
<td>Department of Clinical Medicine, University of Helsinki</td>
</tr>
<tr>
<td>Lohi</td>
<td>Hannes</td>
<td>x</td>
<td>Research Director, Professor</td>
<td>Department of Veterinary Biosciences, Department of Medical Genetics, Program in Molecular Medicine, University of Helsinki</td>
</tr>
<tr>
<td>Ahonen</td>
<td>Saija</td>
<td></td>
<td>Doctoral Candidate</td>
<td>Department of Veterinary Biosciences, Department of Medical Genetics, Program in Molecular Medicine, University of Helsinki</td>
</tr>
<tr>
<td>Hytönen</td>
<td>Marjo</td>
<td></td>
<td>Doctoral Candidate</td>
<td>Department of Veterinary Biosciences, Department of Medical Genetics, Program in Molecular Medicine, University of Helsinki</td>
</tr>
<tr>
<td>Jokinen</td>
<td>Päivi</td>
<td></td>
<td>Doctoral Candidate</td>
<td>Department of Veterinary Biosciences, Department of Medical Genetics, Program in Molecular Medicine, University of Helsinki</td>
</tr>
<tr>
<td>Koskinen</td>
<td>Lotta</td>
<td></td>
<td>Doctoral Candidate -&gt; Postdoctoral</td>
<td>Department of Veterinary Biosciences, Department of Medical Genetics, Program in Molecular Medicine, University of Helsinki</td>
</tr>
<tr>
<td>Kyöstilä</td>
<td>Kaisa</td>
<td></td>
<td>Doctoral Candidate</td>
<td>Department of Veterinary Biosciences, Department of Medical Genetics, Program in Molecular Medicine, University of Helsinki</td>
</tr>
<tr>
<td>Nevalainen</td>
<td>Elisa</td>
<td></td>
<td>Postdoctoral Researcher</td>
<td>Department of Veterinary Biosciences, Department of Medical Genetics, Program in Molecular Medicine, University of Helsinki</td>
</tr>
<tr>
<td>Niskanen</td>
<td>Alina</td>
<td></td>
<td>Doctoral Candidate</td>
<td>Department of Veterinary Biosciences, Program in Molecular Medicine, University of Helsinki</td>
</tr>
<tr>
<td>Seppälä</td>
<td>Elja</td>
<td></td>
<td>Postdoctoral Researcher</td>
<td>Department of Veterinary Biosciences, Program in Molecular Medicine, University of Helsinki</td>
</tr>
<tr>
<td>Tiira</td>
<td>Katriina</td>
<td></td>
<td>Postdoctoral Researcher</td>
<td>Department of Veterinary Biosciences, Program in Molecular Medicine, University of Helsinki</td>
</tr>
<tr>
<td>Palotie</td>
<td>Aarno</td>
<td>x</td>
<td>Professor</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
</tr>
<tr>
<td>Name</td>
<td>Position</td>
<td>Institute</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td>---------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anttila Verneri</td>
<td>Doctoral candidate</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kallela Mikko</td>
<td>University Researcher</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Luukkonen Tiia</td>
<td>Doctoral candidate</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muona Mikko</td>
<td>Doctoral candidate</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pietiläinen Olli</td>
<td>Doctoral candidate</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wessman Majja</td>
<td>University Researcher</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peltonen-Palotie</td>
<td>Research Director, Professor</td>
<td>Department of Medical Genetics, University of Helsinki and Institute for Molecular Medicine Finland FIMM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hennah William</td>
<td>Doctoral candidate</td>
<td>Department of Medical Genetics, University of Helsinki and Institute for Molecular Medicine Finland FIMM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Largeau Marine</td>
<td>Doctoral candidate</td>
<td>Department of Medical Genetics, University of Helsinki and Institute for Molecular Medicine Finland FIMM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Naukkarinen Jussi</td>
<td>Doctoral candidate</td>
<td>Department of Medical Genetics, University of Helsinki and Institute for Molecular Medicine Finland FIMM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nyman Emma</td>
<td>Doctoral candidate</td>
<td>Department of Medical Genetics, University of Helsinki and Institute for Molecular Medicine Finland FIMM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Palo Marika</td>
<td>Doctoral candidate</td>
<td>Department of Medical Genetics, University of Helsinki and Institute for Molecular Medicine Finland FIMM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Silander Kaisa</td>
<td>University Researcher</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soronen Jarkko</td>
<td>Doctoral candidate</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tomppo Liisa</td>
<td>Doctoral candidate</td>
<td>Department of Medical Genetics, University of Helsinki and Institute for Molecular Medicine Finland FIMM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varilto Teppo</td>
<td>University Researcher</td>
<td>Department of Medical Genetics, University of Helsinki and Institute for Molecular Medicine Finland FIMM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wedenoja Juho</td>
<td>Doctoral candidate</td>
<td>Department of Medical Genetics, University of Helsinki and Institute for Molecular Medicine Finland FIMM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ripatti Samuli</td>
<td>Research Director</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kettunen Johannes</td>
<td>Doctoral candidate - Postdoctoral researcher</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laurila Pirikka-Pekka</td>
<td>Doctoral candidate</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rehnström Karola</td>
<td>Postdoctoral researcher</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rossi Mari</td>
<td>Doctoral candidate</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surakka Ida</td>
<td>Doctoral candidate</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saarela Janna</td>
<td>Research Director</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jakkula Evelina</td>
<td>Postdoctoral researcher</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kallio Suvi</td>
<td>Doctoral candidate</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kemppinen Aru</td>
<td>Doctoral candidate</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leppä Virpi</td>
<td>Doctoral candidate</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulonen Anna-Maija</td>
<td>Doctoral candidate</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saavalainen Päivi</td>
<td>Senior researcher</td>
<td>Research program for Molecular Medicine &amp; Department of Medical Genetics, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Braicu Ovidiu</td>
<td>Doctoral candidate</td>
<td>Research program for Molecular Medicine &amp; Department of Medical Genetics, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dukes Emma</td>
<td>Postdoctoral researcher</td>
<td>Research program for Molecular Medicine &amp; Department of Medical Genetics, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Einarsdottir Elisabet</td>
<td>Postdoctoral researcher</td>
<td>Research program for Molecular Medicine &amp; Department of Medical Genetics, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haimila Katri</td>
<td>Doctoral candidate</td>
<td>Finnish Red Cross Blood Transfusion Service</td>
<td></td>
<td></td>
</tr>
<tr>
<td>de Kauwe Andrea</td>
<td>Postdoctoral researcher</td>
<td>Institute for Molcular Medicine &amp; Department of Medical Genetics, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Löystynoja Katja</td>
<td>Doctoral candidate</td>
<td>Research program for Molecular Medicine &amp; Department of Medical Genetics, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parmar Amarjit</td>
<td>Doctoral candidate</td>
<td>Research program for Molecular Medicine &amp; Department of Medical Genetics, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zibermna Fabiana</td>
<td>Postdoctoral researcher</td>
<td>Research program for Molecular Medicine &amp; Department of Medical Genetics, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taskinen Marja-Riitta</td>
<td>Professor, Research Director</td>
<td>Institute of Clinical Medicine, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Graner Marit</td>
<td>Senior scientist, University lecturer</td>
<td>Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hakkarainen Antti</td>
<td>Graduate student</td>
<td>Institute of Clinical Medicine, UH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hiukka Anne</td>
<td>Postdoctoral Researcher</td>
<td>Institute of Clinical Medicine, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kahri Juhani</td>
<td>Senior scientist, University lecturer</td>
<td>Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lundbom Jesper</td>
<td>Doctoral Candidate</td>
<td>Institute of Clinical Medicine, UH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number</td>
<td>Name</td>
<td>Title</td>
<td>Institution</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>--------------------</td>
<td>------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>97</td>
<td>Lundbom Nina</td>
<td>Senior scientist, University Lecturer</td>
<td>Helsinki University Central Hospital, Institute of Clinical Medicine, UH</td>
<td></td>
</tr>
<tr>
<td>98</td>
<td>Maranghi Marianna</td>
<td>Postdoctoral Researcher</td>
<td>Sapienza University, Rome, Italy</td>
<td></td>
</tr>
<tr>
<td>99</td>
<td>Matikainen Niina</td>
<td>Senior scientist, University lecturer</td>
<td>Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki</td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>Nakaniishi Shuhei</td>
<td>Post doctoral researcher</td>
<td>Department of Endocrinology and Metabolism, Hiroshima University Hospital, Japan</td>
<td></td>
</tr>
<tr>
<td>101</td>
<td>Rautaheimo Emmi</td>
<td>Graduate student</td>
<td>Institute of Clinical Medicine, UH</td>
<td></td>
</tr>
<tr>
<td>102</td>
<td>Rimpilä Olga</td>
<td>Doctoral candidate</td>
<td>Institute of Clinical Medicine, University of Helsinki</td>
<td></td>
</tr>
<tr>
<td>103</td>
<td>Söderlund Sanni</td>
<td>Doctoral Candidate</td>
<td>Institute of Clinical Medicine, University of Helsinki</td>
<td></td>
</tr>
<tr>
<td>104</td>
<td>Tikkonen Helena</td>
<td>Doctoral candidate</td>
<td>Institute of Clinical Medicine, University of Helsinki</td>
<td></td>
</tr>
<tr>
<td>105</td>
<td>Watanabe Hiroshi</td>
<td>Post doctoral researcher</td>
<td>Department of Endocrinology and Metabolism, Hiroshima University Hospital, Japan</td>
<td></td>
</tr>
<tr>
<td>106</td>
<td>Tuomi Tiinamaija</td>
<td>Professor</td>
<td>Research Program for Molecular Medicine &amp; Institute of Clinical Medicine, Department of Medicine, University of Helsinki</td>
<td></td>
</tr>
<tr>
<td>107</td>
<td>Andersen Mette</td>
<td>Doctoral candidate</td>
<td>Research Program for Molecular Medicine &amp; Institute of Clinical Medicine, Department of Medicine, University of Helsinki</td>
<td></td>
</tr>
<tr>
<td>108</td>
<td>Isomaa Bo</td>
<td>University Researcher</td>
<td>Research Program for Molecular Medicine &amp; Institute of Clinical Medicine, Department of Medicine, University of Helsinki</td>
<td></td>
</tr>
<tr>
<td>109</td>
<td>Lehtovirta Miki</td>
<td>Doctoral candidate</td>
<td>Research Program for Molecular Medicine &amp; Institute of Clinical Medicine, Department of Medicine, University of Helsinki</td>
<td></td>
</tr>
<tr>
<td>110</td>
<td>Liljeström Brita</td>
<td>Doctoral candidate</td>
<td>Research Program for Molecular Medicine &amp; Institute of Clinical Medicine, Department of Medicine, University of Helsinki</td>
<td></td>
</tr>
<tr>
<td>111</td>
<td>Lundgren Virve</td>
<td>Doctoral candidate</td>
<td>Research Program for Molecular Medicine &amp; Institute of Clinical Medicine, Department of Medicine, University of Helsinki</td>
<td></td>
</tr>
<tr>
<td>112</td>
<td>Matintupa Olle</td>
<td>Undergraduate student</td>
<td>Research Program for Molecular Medicine &amp; Institute of Clinical Medicine, Department of Medicine, University of Helsinki</td>
<td></td>
</tr>
<tr>
<td>113</td>
<td>Saloranta Carola</td>
<td>Postdoctoral Researcher</td>
<td>Research Program for Molecular Medicine &amp; Institute of Clinical Medicine, Department of Medicine, University of Helsinki</td>
<td></td>
</tr>
<tr>
<td>114</td>
<td>Stoor Linda</td>
<td>Undergraduate Student</td>
<td>Research Program for Molecular Medicine &amp; Institute of Clinical Medicine, Department of Medicine, University of Helsinki</td>
<td></td>
</tr>
<tr>
<td>115</td>
<td>Vehkavaara Satu</td>
<td>Postdoctoral Researcher</td>
<td>Research Program for Molecular Medicine &amp; Institute of Clinical Medicine, Department of Medicine, University of Helsinki</td>
<td></td>
</tr>
<tr>
<td>116</td>
<td>Widen Elisabeth</td>
<td>Senior researcher</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
<td></td>
</tr>
<tr>
<td>117</td>
<td>Cousminer Diana</td>
<td>Doctoral candidate</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
<td></td>
</tr>
<tr>
<td>118</td>
<td>Leinonen Jaakko</td>
<td>Doctoral candidate</td>
<td>Institute for Molecular Medicine Finland FIMM, University of Helsinki</td>
<td></td>
</tr>
</tbody>
</table>
Name of the RC\textquotesingle s responsible person: Kaprio, Jaakko

E-mail of the RC\textquotesingle s responsible person:

Name and acronym of the participating RC: Complex Disease Genomics Group, CompDisGen

The RC\textquotesingle s research represents the following key focus area of UH: 2. Elämän perusrakenne – The basic structure of life

Comments for selecting/not selecting the key focus area: Genetics and genomics is a fundamental part of the basic structure of living organisms. Our RC is focused on the genetics and genomics of complex diseases and has thus also relevance to clinical medicine, another focus area of the University.

**BACKGROUND INFORMATION**

**1 MODERN AND DEMOCRATIC UNIVERSITY OF HELSINKI**

**FOCUS AND QUALITY OF RC\textquotesingle S RESEARCH (MAX. 8800 CHARACTERS WITH SPACES)**

- **Description of the RC\textquotesingle s research focus, the quality of the RC\textquotesingle s research (incl. key research questions and results) and the scientific significance of the RC\textquotesingle s research for the research field(s).**

  Focus. The RC combines two strong traditions of Finnish disease genetics and epidemiology. We aim at unraveling fundamental disease mechanisms using cutting-edge, genome-wide technology and exceptional study collections. This line of research has been one of the national success stories of the highest possible international standard. The foundations were laid already in the 1960s by visionary pediatricians who identified over 30 Mendelian diseases enriched in Finland and by trailblazing epidemiologists who created unique national population cohorts, including twin cohorts, and fostered the use of medical registers. During the last two decades, members of this RC have produced a wave of pioneering discoveries and trained new generations of internationally successful scientists by combining exceptional study collections and molecular techniques.

  The RC covers a large spectrum of topics related to disease genomics reaching from Mendelian to complex traits. Disease areas include cardiovascular, metabolic, neurodevelopmental, neuropsychiatric and immunomediated traits. Past highlights include the cloning of dozens of Mendelian disease genes using family-based positional cloning strategies, and lately, using genome-wide association (GWA) studies in the identification of dozens of common variants associated with complex traits. A key component of the past, current and future success has been, and will be, strong international partnering that enables the best possible combination of unique Finnish study collections and advanced molecular techniques. Although common variants identified by GWA studies have revealed a wealth of disease pathways and stimulated a wave of functional studies, the identified variants explain only a relatively small part of the genetic variance of complex traits. Thus the RC has invested in the next wave of discovery tools. Members of the RC are key partners in massive next-generation sequencing studies that aim to identify low-frequency variants contributing to cardiovascular, metabolic, neurodevelopmental and neuropsychiatric traits. Furthermore, the RC has been investing strongly in unique model organisms to improve our understanding of several neurological traits. For example, the RC houses one of the largest canine biobanks in the world.

  The national tradition in genetics, investments in biobanks, strong basic and clinical science and the physical proximity of Biomedicum to the Helsinki University Central Hospital provide unique opportunities to promote translational research. Members of the RC have pioneered molecular diagnostics for several Mendelian traits. The transition from the research laboratory to true clinical
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC STAGE 2 MATERIAL

diagnostics has been exceptionally fast and effortless. In the future, the RC aims to develop the tools and knowledge for personalized medicine by improved understanding of gene-gene and gene-environment interaction, individual variation in the regulation of gene expression and epigenetics. Unique clinical and population-based tissue collections provide exceptional opportunities to significantly contribute to this field of research.

One of the hallmarks of this RC is its strong partnership with major international research centers and their infrastructures. Members of the RC have faculty positions in the Karolinska Institute in Sweden, the Broad Institute in the United States and the Sanger Institute in the United Kingdom. These partnerships facilitate key roles in large international pioneering projects. Such current projects include the 1000genomes project and the UK10K project (www.uk10k.org).

Quality. The quality of our research is outstanding in terms of publications, external grants, doctoral theses, honors and prizes. The PIs of the RC include scientists whose expertise is recognized worldwide, and who have strong records in respective fields. Many of the PIs belong to the Academy of Finland Center of Excellence in Complex Disease Genetics and to the Nordic Center of Excellence in Disease Genetics. Many of our PIs also have international affiliations. Our RC has generated dozens of new doctoral students and postdoctoral researchers and has published over 800 articles in the years 2005-2010, many in the highest-impact journals across biomedical and clinical science, including at least 12 papers in Nature, 44 in Nature Genetics, 3 in Science, 9 in NEJM and Lancet respectively, 15 in PlosGenet, and 24 in AJHG. The PIs are highly cited, very productive and successful in generating external grants. An ERC Starting Independent Researcher Grant was awarded to Hannes Lohi in 2010, and the Marie Curie Excellence Grant to Päivi Saavalainen in 2005. One of the largest International studies closely integrated with the RC is the ENGAGE integrated project of the FP7 program of the European Union, for which our RC at the University of Helsinki is the lead coordinator. This 12 Mr€ project focuses on pooling datasets across more than 120 000 GWA studies in traits related to the metabolic syndrome, cardiovascular diseases and obesity, as well as on characterizing joint actions between genetic profiles and lifestyle. A multisite NIDA/NCI funding aims to identify functional genes for nicotine dependence on chromosome 22. Newly-funded or impending EU FP7 projects we are involved in include TORNADO (gut microbe – dietary interactions in obesity and metabolic diseases); GENODISC (structural and functional genomics of intervertebral disc degeneration); BioSHARE (Biobank Standardization and Harmonization); SYNNSYS (A European Exert Network in Building Synapse). In addition, we continue to collaborate with existing EU projects such as EUROHEAD, DIogenES, EUROCLOT, GESA, EPICURE, LUPA (dog genomics) and SGene. The research area developed by the RC in human disease genetics is also highly recognized among the general public according to the Finnish Science Barometer 2010. The RC has internationally prominent scientists as its PIs, with memberships in international bodies such as the Nobel Committee for Physiology or Medicine.

Scientific significance. Through active collaboration between the partners in the RC, and with scientists and laboratories outside the RC nationally and internationally, the RC has contributed strongly to new knowledge of the genetic basis of common diseases and their risk factors. The variants identified in GWA studies have stimulated research to understand their impact on cellular, individual and population levels. Well-characterized, large epidemiological Finnish collections provide a special opportunity to study the contribution of individual variants, combination of variants and their cross talk with environmental and lifestyle factors on disease susceptibility at different stages of life. Our RC has also developed unique animal models of for example mice and dogs to further help to identify and model the molecular background and pathogenesis of human inherited diseases. Through active collaboration between the partners in the RC with scientists and laboratories outside the RC at the University of Helsinki, as well as with other research groups nationally and internationally, the RC has contributed
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC STAGE 2 MATERIAL

strongly to new knowledge of the genetic basis of common diseases and their risk factors. Besides our internationally reputed scientific input, the RC’s expertise and scientific significance span technologies, epidemiology and sample collection as well as biobanking and analyses and translational activities including animal models and preclinical trials.

**Ways to strengthen the focus and improve the quality of the RC’s research.**

The RC will further develop its collaboration between its PIs to efficiently utilize new possibilities in genomic medicine and systems biology, including technical resources and know-how for biobanking, robotics and data handling as well as next-generation sequencing. The present availability of genome-wide variation data within the RC members in various case-control studies and prospective cohorts provides excellent possibilities to share the information and thus improve efforts to dissect the genetic background of multiple traits across the members. The high-quality epidemiological cohorts of Finland will be used to study the public-health impact of novel genes and explore gene-environment interactions. Extensive animal resources established within the RC will be utilized more efficiently in order to translate and replicate the discoveries across species. The RC will maintain its close links to frontline international genomic institutes and continue to contribute to world-class biobanking initiatives that provide outstanding replication resources.

---

### 2 PRACTICES AND QUALITY OF DOCTORAL TRAINING (MAX. 8800 CHARACTERS WITH SPACES)

**How is doctoral training organised in the RC? Description of the RC’s principles for recruitment and selection of doctoral candidates, supervision of doctoral candidates, collaboration with faculties, departments/institutes, and potential graduate schools/doctoral programmes, good practises and quality assurance in doctoral training, and assuring good career perspectives for the doctoral candidates/fresh doctorates.**

The RC groups have extensive experience in the training of graduate students and postdoctoral fellows and the group leaders have all been involved in several graduate schools. The courses and tutoring organized by graduate schools at the University of Helsinki have provided the framework for the training of the RC’s researchers. Each graduate student has a thesis committee with scientists from outside the RC. The RC has trained numerous scientists, with 54 PhDs defended at the University of Helsinki in 2005-2010. Currently we have 34 enrolled PhD students. Seventeen RC members have acted as supervisors during 2005-2010.

Most of the PhD students in the RC go on to defend their theses in the Medical faculty, some in other faculties of the University. The Faculty of Medicine offers the following scientific postgraduate degrees: Doctor of Medical Science, Doctor of Dental Science and Doctor of Philosophy. A doctoral student participates in a research project, writes a doctoral dissertation and completes the studies required for the degree (40 ECTS credits for Medical or Dental Science, 60 ECTS credits for PhD). The student is expected to become well-versed in the basic problems and research methods of scientific and medical research.

To promote close integration of basic and clinical research, multidisciplinary five-year research programs were established in 2001, comprising the Research Programs Unit of the Faculty of Medicine, of which the Molecular Medicine program is a key component of the present RC. Many of the RC’s PIs act as group leaders in the Centre of Excellence in Complex Disease Genetics, one of the highest-level research units funded by the Academy of Finland. PhD students are recruited to these research groups either using external funds of the research group or funds allocated on a competitive basis to Graduate schools by the Ministry of Education. The Meilahti medical campus has also a modern infrastructure with top-level methodological support. In addition to an excellent training environment, the graduate schools
organize structured PhD training with various international courses, workshops and symposia on the campus.

Ministry of Education or University of Helsinki funded graduate schools and research training programs offer broad training opportunities in e.g. biomedicine, clinical medicine, biology, epidemiology and biocomputing. Graduate schools are often arranged nationally and are active internationally by organizing visits and seminars and supporting student mobility (e.g. by offering travel and lab visit grants). The programs apply for funding in fixed terms and admit students through an open call. Principal Investigators within the RC also have some international training positions available through NIH and EU-funded grants. The medical faculty has a joint PhD program with the Karolinska Institute, and this cooperation is being expanded to other universities as well. There are nine Ministry of Education funded graduate schools on the Meilahti campus and the RCs students study in several of these. This is natural given the cross-disciplinary nature of the RC.

Each of our students has 1-2 designated supervisors and currently students enrolled to the graduate schools also have a two-person thesis committee, with whom they meet annually to review progress. Written reports on these meetings are created and serve to document the evaluation of the student. Each graduate student will have a study group meeting once a year and the study group may contain also scientists outside the RC. Postdoctoral students are also responsible for organizing and running weekly journal clubs and for giving their contribution to seminars within the RC (CoE, Mol Med program, department seminars, etc) they also take part in annual scientific retreats and national and international congresses. These basic structures provide an interactive and stimulating environment for students working on different projects.

Some of our students also participate in the Faculty’s MD, PhD program. The M.D., Ph.D. program of the Medical Faculty of the University of Helsinki offers students a chance to begin working towards a Ph.D. thesis already in the beginning of their medical or dental studies. Students are selected in the program every year from among first-year medical or dental students. They begin in the program after finishing their first year of medical school, doing postgraduate research alongside their M.D. studies. Two postdoctoral tutors and one or two student tutors guide the students during their first years in the program.

Before finishing their medical or dental studies, the M.D., Ph.D. students work in research groups for five summers, each summer for three months on a monthly salary. During the first two summers the students have a unique chance to carry out research rotations in 3-4 different research groups. This enables the students to familiarize themselves with various themes of research. After their second summer in the program the students begin their Ph.D. thesis project in a Medical faculty research group. Each student is appointed a thesis committee to support the progress of the thesis project.

After the students have finished their medical or dental degree they continue with full-time research for a period of up to two years, during which time they are expected to finish their Ph.D. thesis. When the students are granted their doctoral degree they will also receive a diploma for the M.D., Ph.D. program. M.D., Ph.D. students also have the opportunity to partake in seminars, symposia and courses and are offered travel grants for participating in international conferences. The Faculty and its committees relevant for graduate education have committed much time and effort into assuring a structure and high-quality process for PhD studies. After graduation, students continue onto postdoctoral positions, often in excellent institutions abroad. Some continue with clinical work in medicine or veterinarian medicine. It is difficult to evaluate the long-term prospects of those who have graduated in the years
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC STAGE 2 MATERIAL

2005-2010, but based on earlier experiences of the PIs, our graduate students have pursued excellent and productive career paths.

- RC’s strengths and challenges related to the practises and quality of doctoral training, and the actions planned for their development.

The Medical Faculty of the University of Helsinki has pioneered many developments in order to ensure the best possible scientific and pedagogical quality of PhD studies. These practices and processes are documented in the quality assurance documents of the Faculty, and approved in the recent evaluation of the University. Many RC members have participated in these developments as members of the standing and ad hoc committees and working groups established by the Faculty. For example, the Faculty pioneered the introduction of the TUHAT electronic documentation service and has set up strict requirements for the recruitment, evaluation and education of PhD students. The RC will follow the best practices set out by the Faculty and contribute to the continued development of these processes.

3 SOCIETAL IMPACT OF RESEARCH AND DOCTORAL TRAINING (MAX. 4400 CHARACTERS WITH SPACES)

- Description of how the RC interacts with and contributes to the society (collaboration with public, private and/or 3rd sector).

The Medical Faculty of the University of Helsinki is the flagship of Finnish medical research. Basic biomedical research, clinical research and epidemiological research all represent areas of special strength in Finnish science and research. The RC and its PIs are active in giving presentations to the general public and are frequently interviewed by the media in connection to their scientific breakthroughs. The research area in human disease genetics is also highly recognized and valued among the general public. Many of the RC’s PIs are also internationally prominent scientists with memberships in international committees such as the Nobel Committee for Physiology or Medicine.

The Faculty of Medicine, as well as other organizations on the Meilahti medical campus, are experts in the field of health care. The Faculty strives to influence national health care and to maintain good contacts with industry. The Faculty’s most important partner is the Hospital District of Helsinki and Uusimaa, where several of our PIs practice as clinicians. One of the Faculty’s key duties is to consolidate and develop University-led activities in hospitals belonging to the University Hospital. The RC provides expertise in human genetics, complex disease genetics and public health genomics. Thus it provides direct input into medical care and preventive/screening services.

- Ways to strengthen the societal impact of the RC's research and doctoral training.

Our research and doctoral training is highly relevant to the society at large. Our high-quality research serves to ensure first-rate medical treatment, particularly with respect to both the genetics of monogenic disorders and the genomics of complex diseases. By identifying individual differences in the response to changing environments and over the course of an individual’s life, public health genomics will be of increasing importance as the genomic architecture of many disorders is unraveled. Close interaction with health care providers (e.g. HUCH), state research institutes and policy makers will be strengthened further to increase the impact of our research in Finland. High-impact publications, a proactive role in international scientific organizations (such as the FIMM-EMBL), and constructive interaction with funders (such as the EU) are all means of providing societal impact internationally.
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC STAGE 2 MATERIAL

4 INTERNATIONAL AND NATIONAL (INCL. INTERSECTORAL) RESEARCH COLLABORATION AND RESEARCHER MOBILITY (MAX. 4400 CHARACTERS WITH SPACES)

- Description of the RC’s research collaborations and joint doctoral training activities and how the RC has promoted researcher mobility.

Our research spans national and international collaborations. Within the University of Helsinki, we work across faculties and research institutes. The most important ones are FIMM and the Research Programs Unit of the Faculty of Medicine. We are in close collaboration with the National Institute for Health and Welfare, other state research institutes, other Finnish Universities and the Biocenter Finland. Many of our PIs have also longstanding international affiliations.

One of the largest International studies closely integrated with the RC is the ENGAGE integrated project of the FP7 program of EU of which the University of Helsinki is the lead coordinator. This 12 M€ project focuses on pooling datasets across more than 120,000 GWA studies in traits related to the metabolic syndrome, cardiovascular diseases and obesity and characterizing joint actions between genetic profiles and lifestyle. Through this project, we have contributed to and lead multiple other collaborative studies, that have lead to the identification of hundreds of new genetic variants and genes for dozens of common diseases and traits. Further funding is needed to characterize the functional nature and public-health impact for these discoveries. Thus, a multisite NIDA/NCI funding is directed to the identification of functional genes for nicotine dependence on chromosome 22, while another NIAAA grant has funded genotyping of the FT12 study sample for the purpose of discovering gene-environment interactions. Newly funded or impending EU FP7 projects we are involved in include TORNADO (gut microbe – dietary interactions in obesity and metabolic diseases); GENODISC (structural and functional genomics of intervertebral disc degeneration); BioSHARE (Biobank Standardization and Harmonization); SYNSYS (A European Exert Network in Building Synapase) and i.Family (Determinants of eating behaviour in European children, adolescents and their parents), in addition to continuing our collaborations in existing EU projects such as EUROHEAD, DIOGENES, EUROCLOT, GEHA, EPICURE, LUPA (dog genomics) and SGENE. The Marie Curie Excellence Grant CD-GENETICS enabled international recruitment of various postdoctoral researchers and PhD students from abroad. Because of the role of our RC investigators in the Wellcome Trust Sanger Institute, the Broad Institute and the Karolinska Institute, they make a strong contribution to large international collaborative efforts. This guarantees us excellent access to data produced by projects like Hapmap3, 1000 Genomes and EUVADIS (sequencing 1000 individuals with early onset cardiovascular and metabolic diseases). These collaborations also harmonize operations of CoE with critical Nordic operators in biobanking and disease databases (Nordic Center of Excellence, www.ncoedg.org).

Within these projects, there have been excellent opportunities for researcher training and mobility. Just to take one example, the University of Helsinki is the Work Package leader in ENGAGE for training and mobility. Many workshops and research-exchange visits across Europe have thus been made possible. PhD students, postdoctoral researchers and senior researchers frequently visit laboratories in Europe, the US and Asia, and their scientists visit us in turn.

- RC’s strengths and challenges related to research collaboration and researcher mobility, and the actions planned for their development.

The RC has a rich and productive history of research collaboration. In particular, the past 5-10 years have seen a vast increase in the number of multicentre studies needed for the discovery of genetic variants underlying many complex disorders. One challenge will be to maintain our good infrastructure and high level of expertise, as well as to continue to spearhead international collaborations. In order to
maintain our expertise in the scientific and administrative aspects of these collaborations sufficient funds are needed from the University. The same resources are needed for national collaborations as it can be envisioned that there will be increasing pressure to avoid duplicate efforts within Finland. The Biocentre Finland is an important step in this direction.

Researcher mobility also requires continued resources, not only for the visiting student or postdoctoral researcher but also for the host organization. Improving the efficiency of fund allocation represents a challenge for the centralized bureaucracy of the University of Helsinki.

**OPERATIONAL CONDITIONS (MAX. 4400 CHARACTERS WITH SPACES)**

- Description of the operational conditions in the RC’s research environment (e.g. research infrastructure, balance between research and teaching duties).

  The RC comprises the best overall expertise in complex disease genetics at the University of Helsinki, as well as the rest of Finland, and is acknowledged worldwide. The RC’s expertise spans technologies, epidemiology and sample collection, biobanking, analyses and translational activities including animal models and preclinical trials. The RC plays a key role in the development and maintenance of infrastructure for state-of-the-art genetic and genomic research. Many of the RC members are clinicians or university teachers who balance between their clinical and teaching duties and research.

  The Medical Faculty of the University of Helsinki is the flagship of Finnish medical research. The Faculty of Medicine is located on the Meilahti Medical Campus together with the Helsinki University Hospital and other research and educational facilities.

  We work across faculties and research institutes, and the medical campus in Helsinki is highly rated in all international evaluations. The most important agents are FIMM and the Research Programs Unit of the Faculty of Medicine. We are in close collaboration with national agents and internationally. In January of 2011, the Academy of Finland awarded FIMM 4 million euros for the infrastructure development of biobanks. An important element is the FIMM Technology Centre, which is a local, national and international infrastructure and service facility developing new technologies and serving the user community with state-of-the-art technologies. The FIMM Technology Centre has excellent research facilities, including high and medium-throughput systems for genotyping sequencing, transcript profiling, high-throughput RNAi screening and translational technologies. To serve the needs of computation and data management the FIMM Technology Centre has set up a 1000 cpu cloud computing environment in collaboration with CSC and continues to increase its capacity for the storage array network (SAN). The FIMM Technology Centre maintains over hundred physical and virtual servers used for hosting bioinformatics databases and other applications. The Centre utilizes the latest IT tools such as virtualization and scale-out storage technologies to provide a robust and scalable platform for doing date-intensive science. Collaboration with the Centre for Scientific Computing (www.CSC.fi) enables the usage of CSC facilities when very high capabilities are needed. Based on the development of this outstanding expertise, infrastructure and reputation the RC has been eminently successful in external grant competitions. This in turn permits us to attract gifted students for PhD studies and postdoctoral work. FIMM also coordinates Biomedinfra – a joint national hub for the European ESFRI infrastructure projects BBMRI, ELIXIR, EATRIS.

- RC’s strengths and challenges related to operational conditions, and the actions planned for their development.

  The cross-disciplinary nature of the RC and its basis at the medical campus of the University of Helsinki are great strengths.
Modern disease genomics utilize high-throughput genomic techniques, interdisciplinary strategies and very large sample sizes. In this type of research no institute can be self-sufficient. Success in modern disease genomics is based on international collaboration. Such collaboration is greatly facilitated by joint appointments and exchange of researchers between institutions. Within our RC this is documented by the large number of milestone publications in some of the most prestigious scientific journals, which are nearly all based on large international collaborations.

**Description of the execution and processes of leadership in the RC, how the management-related responsibilities and roles are distributed in the RC and how the leadership- and management-related processes support high quality research, collaboration between principal investigators and other researchers in the RC, the RC’s research focus and strengthening of the RC’s know-how.**

The RC includes PIs from the Research Program for Molecular Medicine, the Centre of Excellence in Complex Disease Genetics and the genetics program of FIMM. These entities were largely established and spearheaded by Leena Peltonen-Palotie, an innovative and inspiring leader and one of the most famous geneticists in the world. Leena’s exceptional domestic and international connections to leading scientists and funding organizations in the field have helped to develop the necessary infrastructure and know-how so that the RC has become an outstanding internationally recognized leader in human genetics. Having strong leadership has improved the quality of our research and facilitated the competitiveness of the RC in scientific evaluations. Most of the RC members belong to the flagships of Finnish high-quality research institutions, including CoE in Complex Disease Genetics and FIMM. Effective leadership processes have included regular joint top-quality seminar series, regular meetings between PIs and active encouragement for data sharing to expedite each PI’s research progresses. Our leadership has also carried great responsibility for doctoral training and the establishment of a new generation of young PIs to ensure the continuation of the Finnish tradition in genetics. The RC’s PIs meet regularly to discuss common scientific, methodological and other research-related issues. The leadership of the RC has been supported by administrative assistance in financial, personnel and office matters. The RC maintains several technical core facilities such as those for sequencing, genotyping and bioinformatics, all of which improve the efficiency and cost-benefit of the RC. The RC members share facilities and make joint investments for new equipments to facilitate the maintenance, use and know-how of the state-of-the-art infrastructure. This has significantly improved collaboration between individual research groups.

**RC’s strengths and challenges related to leadership and management, and the actions planned for developing the processes.**

The research field of the RC develops rapidly and strong leadership is required to maintain the exceptionally diverse and high quality of our research. New high-throughput sequencing technologies are becoming the golden standard in genetics in the near future. The role of leadership is to make sure the RC is kept up-to-date on the latest developments infrastructure. The leadership provides guidance on the application and interpretation of important research questions within the RC’s projects. The RC’s extensive collaboration on all fronts with scientists all over the world will help in achieving this. In our RC, challenges arising from the untimely death of Leena Peltonen have been addressed jointly by the PIs to ensure a stable transition for her PhD students and projects. Good leadership will ensure that all arising issues are regularly discussed between PIs, proper training is provided for scientists, and a collaborative environment facilitates the application of new developments to advance each project.
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC STAGE 2 MATERIAL

7 EXTERNAL COMPETITIVE FUNDING OF THE RC

- Listing of the RCs external competitive funding, where:
  - the funding decisions have been made during 1.1.2005-31.12.2010, and
  - the administrator of the funding is/has been the University of Helsinki

- Academy of Finland (AF) - total amount of funding (in euros) AF has decided to allocate to the RC members during 1.1.2005-31.12.2010: 11200000

- Finnish Funding Agency for Technology and Innovation (TEKES) - total amount of funding (in euros) TEKES has decided to allocate to the RC members during 1.1.2005-31.12.2010: 90000

- European Union (EU) - total amount of funding (in euros) EU has decided to allocate to the RC members during 1.1.2005-31.12.2010: 18600000

- European Research Council (ERC) - total amount of funding (in euros) ERC has decided to allocate to the RC members during 1.1.2005-31.12.2010: 1380000

- International and national foundations - names of international and national foundations which have decided to allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their funding (in euros).
  - names of the foundations: Solhberg Foundation, Finnish Cultural Foundation, Gastroenterology foundation, Pesatu, Nurmi Foundation, Finnish Foundation for Cardiovascular Research, Wallenberg Foundation, European Science Foundation, Novo Nordisk Fonden, KELA, Pfizer Foundation, Sigrid Juselius Foundation, NIH
  - total amount of funding (in euros) from the above-mentioned foundations: 3950000

- Other international funding - names of other international funding organizations which have decided to allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their funding (in euros).
  - names of the funding organizations: Karolinska institutet, AKC Canine Foundation, Swedish Research Council, NordForsk, CIMO, Uppsala University, Indiana University
  - total amount of funding (in euros) from the above-mentioned funding organizations: 3200000

- Other national funding (incl. EVO funding and Ministry of Education and Culture funded doctoral programme positions) - names of other national funding organizations which have decided to allocate funding to the RC members during 1.1.2005-31.12.2010, and the amount of their funding (in euros).
  - names of the funding organizations: EVO, HUSLAB, Biocentrum Helsinki, University of Helsinki Funds, University of Helsinki, National Institute for Health and Welfare (THL), Ministry of Education and Culture, Helsinki Graduate Program in Biotechnology and Molecular Biology GPBM, HBO Graduate School, The Finnish Medical Society Duodecim
  - total amount of funding (in euros) from the above-mentioned funding organizations: 6000000

8 RC’S STRATEGIC ACTION PLAN FOR 2011–2013 (MAX. 4400 CHARACTERS WITH SPACES)
RC-SPECIFIC STAGE 2 MATERIAL

- Description of the RC's future perspectives in respect to research and doctoral training.

Our RC will continue to study the genetic background of common complex diseases and traits using large-scale population and patient cohorts with rich phenotypic and clinical data, and genome-wide profiling. The research will focus on interesting and clinically relevant study questions aiming for the best possible science. While the RC is not a formal organization in itself, we have the necessary structures to maintain our current collaborations and research. As mentioned earlier these exist principally in FIMM and the Faculty of Medicine, but also with our other partners on the Meilahti campus, elsewhere in Finland and abroad. External funding is an absolute requirement for this. At the same time international evaluations have indicated that Finnish research is more dependent on external funding that is the case in many other top-level European research centres. Thus the University must prioritize research and increase the level of internal funding. Doctoral training will also continue to be an integral part of our work.

9 Short description of how the RC members have contributed to the compilation of the stage 2 materials (max. 1100 characters with spaces).

RC members have taken care to submit their own information on publications and other scientific activities, and PIs have written and commented on the texts. Project secretaries have done a wonderful job of compiling all the materials despite the delayed and changing instructions from the evaluation secretariat.
CompDisGen/Kaprio

1 Analysis of publications

- Associated person is one of Jaakko Kaprio, Leena-Helen Bogl, Ulla Heidi Broms
  Anna Kaesi-Rahkonen, Telervo Korthonen, Hanna-Helena Lajunen, Hanna
  Antti Latvola, Anna-Maria Lohola, Linda Marina Miettinen, Minna
  Ollikainen, Hannu Haukela, Suoma Eeva Matilda Saarni, Elna Simola
  Kauko Haavisto, Kati Hannula, Karina Sara Erikkka Hannula
  Jozwik, Juha Kere, Tuuli Kaasinen, Elna Simola
  Alpo Kaisa Kettunen, Tellervo Korhonen, Hanna-Reetta Lajunen, Hanna
  Antti Latvola, Anu-Maria Loukola, Linda Marina Miettinen, Minna
  Ollikainen, Hannu Haukela, Suoma Eeva Matilda Saarni, Elna Simola
  Kauko Haavisto, Kati Hannula, Karina Sara Erikkka Hannula

Publication Year

<table>
<thead>
<tr>
<th>Publication type</th>
<th>2005</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
<th>2009</th>
<th>2010</th>
<th>Total Count 2005 - 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1 Refereed journal article</td>
<td>143</td>
<td>143</td>
<td>157</td>
<td>184</td>
<td>200</td>
<td>173</td>
<td>1000</td>
</tr>
<tr>
<td>A2 Review in scientific journal</td>
<td>4</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>7</td>
<td>20</td>
</tr>
<tr>
<td>A3 Contribution to book/other compilations (refereed)</td>
<td>4</td>
<td>11</td>
<td>3</td>
<td>5</td>
<td>4</td>
<td>27</td>
<td></td>
</tr>
<tr>
<td>A4 Article in conference publication (refereed)</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>B1 Unrefereed journal article</td>
<td>11</td>
<td>9</td>
<td>6</td>
<td>5</td>
<td>9</td>
<td>8</td>
<td>48</td>
</tr>
<tr>
<td>B2 Contribution to book/other compilations (non-refereed)</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>B3 Unrefereed article in conference proceedings</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td></td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C1 Published scientific monograph</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>C2 Edited book, compilation, conference proceeding or special issue of journal</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
<td>4</td>
</tr>
<tr>
<td>D1 Article in professional journal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6</td>
</tr>
<tr>
<td>D2 Article in professional hand or guide book or in a professional data system, or text book material</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>Publication type</td>
<td>2005</td>
<td>2006</td>
<td>2007</td>
<td>2008</td>
<td>2009</td>
<td>2010</td>
<td>Total Count 2005 - 2010</td>
</tr>
<tr>
<td>------------------------------------------------------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------</td>
<td>------------------------</td>
</tr>
<tr>
<td>D3 Article in professional conference proceedings</td>
<td></td>
<td></td>
<td></td>
<td>2</td>
<td></td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>E1 Popular article, newspaper article</td>
<td>4</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>E1 Popular contribution to book/other compilations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>E2 Popular monograph</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td>1</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>H1 Patents</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>
2 Listing of publications

A1 Refereed journal article

2005

Abdel-Rahman, WM, Lohi, H, Knuttila, S, Peltonäki, P, Abdel-Rahman, W. 2005, 'Restoring mismatch repair does not stop the formation of reciprocal translocations in the colon cancer cell line HCA7 but further destabilizes chromosome number', *Oncogene*, vol 24, no. 4, pp. 706-713.


INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF PUBLICATIONS DATA 2005-2010

CompDisGen/Kaprio


INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF PUBLICATIONS DATA 2005-2010

CompDisGen/Kaprio


CompDisGen/Kaprio


Taskinen, M, 'Type 2 diabetes as a lipid disorder', *Current Molecular Medicine*, vol 5, pp. 297-308.


CompDisGen/Kaprio


2006


INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF PUBLICATIONS DATA 2005-2010

CompDisGen/Kaprio


INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TAHUT COMPILATIONS OF PUBLICATIONS DATA 2005-2010

CompDisGen/Kaprio


INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF PUBLICATIONS DATA 2005-2010

CompDisGen/Kaprio


2007
CompDisGen/Kaprio


Holmquist, J, Tiggar, D, Almgren, P, Lyssenko, V, Lindgren, CM, Isomaa, B, Tuomain, T, Berglund, G, Renstrom, E, Groop, L 2007, 'Polymorphisms in the gene encoding the voltage-dependent Ca2+ channel Cav2.3 (CACA1B) are associated with type 2 diabetes and impaired insulin secretion', Diabetologia, vol 50, pp. 2467-2475.


CompDisGen/Kaprio


CompDisGen/Kaprio


CompDisGen/Kaprio


2008


INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF PUBLICATIONS DATA 2005-2010

CompDisGen/Kaprio


Hemila, H. Kaprio, J. 2008, ‘Vitamin E supplementation may transiently increase tuberculosis risk in males who smoke heavily and have high dietary vitamin C intake’, British Journal of Nutrition, vol 100, no. 4, pp. 896-902.


CompDisGen/Kaprio


Orto-Melander, M, Melander, O, Guiducci, C, Tuomi, T, Peltonen, L, Group, L, Taskinen, M 2008, 'Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations', Diabetes, vol 57, no. 11, pp. 3112-3121.


CompDisGen/Kaprio


INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF PUBLICATIONS DATA 2005-2010

CompDisGen/Kaprio


variants clustered in genomic loci and biological pathways affect human height', Nature

INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF PUBLICATIONS DATA 2005-2010

CompDisGen/Kaprio


INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF PUBLICATIONS DATA 2005-2010

CompDisGen/Kaprio


Nature Genetics, vol 42, no. 2, pp. 142-148.


INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF PUBLICATIONS DATA 2005-2010

CompDisGen/Kaprio


A2 Review in scientific journal

2005


2006


INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF PUBLICATIONS DATA 2005-2010

CompDisGen/Kaprio


2007


2008

2009

2010

A3 Contribution to book/other compilations (referred)

2005

2006
CompDisGen/Kaprio


A4 Article in conference publication (referred)


2006 Kere, J 2006, Overview of the SLC26 family and associated diseases.
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF PUBLICATIONS DATA 2005-2010

CompDisGen/Kaprio

2007

2008

2009

2010


B1 Unrefereed journal article

2005


2006


2007

Järvenpää, T, Rinne, JO, Koskenuvu, M, Raaha, I, Kaprio, J 2006, 'Binge drinking and dementia - The authors respond', Epidemiology, vol 17, pp. 484-485.


2007


2008


Lohi, H, Nicholas, FW 2009, ‘Unlocking the genetic make-up of canine hip dysplasia: we can work it out’, Briefings in Bioinformatics.
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF PUBLICATIONS DATA 2005-2010

CompDisGen/Kaprio


2010


B2 Contribution to book/other compilations (non-refereed)

2005


2007


2008


2009

**B3 Unrefereed article in conference proceedings**

2005

Kaprio, J, Broms, UH, Shiffman, S, Madden, PAF. 2005. A study of nicotine dependence in twins based on the NDSS scale., Nicotine & Tobacco Research 7 OXFORD UNIVERSITY PRESS.

2006

Kaprio, J, Dick, D, Huzink, A, Rose, RJ. 2006. Cannabis use among Finnish adolescents and young adults., Behavior Genetics 36 SPRINGER NEW YORK LLC.

2007


C1 Published scientific monograph

2005


C2 Edited book, compilation, conference proceeding or special issue of journal

2005


2006


2008


2009


D1 Article in professional journal

2005


2006


2007

INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF PUBLICATIONS DATA 2005-2010

CompDisGen/Kaprio

2010


2009

2008


2007
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF PUBLICATIONS DATA 2005-2010

**CompDisGen/Kaprio**

2008

2009

**E1 Popular contribution to book/other compilations**

2010

**E2 Popular monograph**

2008

2010

**H1 Patents**

2005
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF OTHER SCIENTIFIC ACTIVITIES 2005-2010

CompDisGen/Kaprio

1 Analysis of activities 2005-2010

Activity type | Count | Activity type | Count |
--- | --- | --- | --- |
Supervisor or co-supervisor of doctoral thesis | 107 | Prizes and awards | 41 |
Editor of research journal | 64 | Peer review of manuscripts | 88 |
Assessment of candidates for academic posts | 12 | Membership or other role in review committee | 12 |
Membership or other role in research network | 13 | Membership or other role in national/international committee, council, board | 169 |
Membership or other role in public Finnish or international organization | 39 | Membership or other role of body in private company/organisation | 8 |
Participation in interview for written media | 59 | Participation in radio programme | 15 |
Participation in TV programme | 18 |
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF OTHER SCIENTIFIC ACTIVITIES 2005-2010

**CompDisGen/Kaprio**

<table>
<thead>
<tr>
<th>Activity type</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participation in interview for web based media</td>
<td>3</td>
</tr>
</tbody>
</table>
## Listing of activities 2005-2010

### Supervisor or co-supervisor of doctoral thesis

**Jaakko Kaprio**
- Supervisor, Doctoral theses: Tuula Kieseppä, Jaakko Kaprio, 1997 → 2005, Finland
- Supervisor, Doctoral theses: Annina Ropponen, Jaakko Kaprio, 1999 → 2006, Finland
- Supervisor, Doctoral theses: Bidet Siamak, Jaakko Kaprio, 2000 → 2008, Finland
- Supervisor, Doctoral theses: Varpu Penninkilämi-Kerola, Jaakko Kaprio, 2000 → 2006, Finland
- Supervisor, Doctoral theses: Marja Heinonen-Guzijev, Jaakko Kaprio, 2001 → 2008, Finland
- Supervisor, Doctoral theses: Suoma Saarni, Jaakko Kaprio, 2001 → 2008, Finland
- Supervisor, Doctoral theses: Marja Heinonen-Guzijev, Jaakko Kaprio, 2001 → 2008, Finland
- Supervisor, Doctoral theses: Varpu Penninkilämi-Kerola, Jaakko Kaprio, 2000 → 2006, Finland
- Supervisor, Doctoral theses: Varpu Penninkilämi-Kerola, Jaakko Kaprio, 2000 → 2006, Finland
- Supervisor, Doctoral theses: Marja Heinonen-Guzijev, Jaakko Kaprio, 2001 → 2008, Finland
- Supervisor, Doctoral theses: Suoma Saarni, Jaakko Kaprio, 2001 → 2008, Finland
- Supervisor, Doctoral theses: Ulla Broms, Jaakko Kaprio, 2001 → 2005, Finland
- Supervisor, Doctoral theses: Kaj Petter, Jaakko Kaprio, 2002 → 2005, Finland
- Supervisor, Doctoral theses: Eero Vuoksima, Jaakko Kaprio, 2003 → 2010, Finland
- Supervisor, Doctoral theses: Elina Shvola, Jaakko Kaprio, 2003 → 2010, Finland
- Supervisor, Doctoral theses: Hanna-Raetta Lajunen, Jaakko Kaprio, 2003 → 2010, Finland
- Supervisor, Doctoral theses: Aki Rogel, Jaakko Kaprio, 2004 → 2008, Finland
- Supervisor, Doctoral theses: Leonie-Helen Bogl, Jaakko Kaprio, 2004 → 2008, Finland
- Supervision of Doctoral Theses: Marja-Lisa Kinnunen, Jaakko Kaprio, 2005, Finland
- Supervision of Doctoral Theses: Heikki Bäckman, Jaakko Kaprio, 2006, Finland
- Supervision of Doctoral Thesis: Anne Viljanen, Jaakko Kaprio, 2006, Finland
- Supervision of Doctoral Thesis: Kristina Tianen, Jaakko Kaprio, 2006, Finland
- Supervision, mentoring and examination of Doctoral Thesis: Katja Walter, Jaakko Kaprio, 01.01.2006 → 31.12.2006, Finland
- Supervisor, Doctoral theses: Juha Häämäläinen, Jaakko Kaprio, 2006 → 2010, Finland
- Supervisor, Doctoral theses: Jyrki Varjoes, Jaakko Kaprio, 2006 → 2010, Finland
- Supervisor, Doctoral theses: Linda Mustelin, Jaakko Kaprio, 2006 → 2010, Finland
- Supervisor, Doctoral theses: Maria Hakkinen, Jaakko Kaprio, 2006 → 2010, Finland

**Anna Keski-Rahkonen**
- Supervisor, doctoral theses: Anu Raevuori, Anna Keski-Rahkonen, 2001 → 2008, Finland

**Tellervo Korhonen**
- Supervisor, Tellervo Korhonen, 2008 → 2010, Finland
- Supervisor, Tellervo Korhonen, 2009 → 2010, Finland

**Juha Kere**
- Supervisor of Doctoral Thesis project: Minna Kujala-Myllynen, Juha Kere, 1998 → 2005, Finland
- Supervisor of Doctoral Thesis project: Johanna Vendelin, Juha Kere, 2003 → 2007, Finland
- Supervisor of Doctoral Thesis project: Nina Ahola, Juha Kere, 2003 → 2007, Finland
- Supervisor of Doctoral Thesis project: Anna Rautanen, Juha Kere, 2001 → 2007, Finland
- Supervisor of Doctoral Thesis project: Erik Melén, Juha Kere, 2001 → 2006, Sweden
- Supervisor of Doctoral Thesis project: Heidi Antholin, Juha Kere, 2001 → 2007, Sweden
- Supervisor of Doctoral Thesis project: Ville Pulkkinen, Juha Kere, 2001 → 2006
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF OTHER SCIENTIFIC ACTIVITIES 2005-2010

CompDisGen/Kaprio

Supervisor of Doctoral Thesis project: Inkeri Tiala, Juha Kere, 2002 → 2009, Finland
Supervisor of Doctoral Thesis project: Tuuli Lappalainen, Juha Kere, 2002 → 2009, Finland
Supervisor of Doctoral Thesis project: Anna Helquist, Juha Kere, 2003 → 2009, Sweden
Supervisor of Doctoral Thesis project: Hanna Peterson, Juha Kere, 2003 → 2010, Sweden
Supervisor of Doctoral Thesis project: Tuula Siljander, Juha Kere, 2003 → 2009, Finland
Supervisor of Doctoral Thesis project: Sara Bruce, Juha Kere, 2004 → 2009, Sweden
Supervisor of Doctoral Thesis project: Lotta Kossinen, Juha Kere, 2005 → 2009, Finland
Supervisor of Doctoral Thesis project: Tiina Järvinen, Juha Kere, 2005 → 2010, Finland

Outi Kaarina Elomaa, Väitöskirjan ohjaus, Outi Kaarina Elomaa, 2009 → ...

Väitöskirja, Katarina Sara Eriikka Hannula-Jouppi, 01.02.2005 → 31.02.2009

Kimmo Kontula, Supervisor of doctoral thesis: Heidi Fodstad, Kimmo Kontula, 2005, Finland
Supervisor of doctoral thesis: Kaisa Valli-Jaakkola, Kimmo Kontula, 2007, Finland
Supervisor of doctoral thesis: Maarii Lappalainen, Kimmo Kontula, 2008, Finland
Supervisor of doctoral thesis: Annukka Marjamaa, Kimmo Kontula, 2009

Supervisor of Doctoral Thesis: Alina Niskanen, Hannes Tapani Lohi, 2008 → ..., Finland
Supervisor of Doctoral Thesis: Helé Venhoranta, Hannes Tapani Lohi, 2008 → ..., Finland
Supervisor of Doctoral Thesis: Anna Kyöstilä, Hannes Tapani Lohi, 2008 → ..., Finland
Supervisor of Doctoral Thesis: Marjo Hytinen, Hannes Tapani Lohi, 2008 → ..., Finland
Supervisor of Doctoral Thesis: Riitta Seppänen, Hannes Tapani Lohi, 2008 → ..., Finland
Supervisor of Doctoral Thesis: Saara Ahonen, Hannes Tapani Lohi, 2008 → ..., Finland
Supervisor of doctoral thesis: Alina Niskanen, Hannes Tapani Lohi, 2008, Finland
Supervisor of Doctoral Thesis: Viví Deckwirth, Hannes Tapani Lohi, 2009 → ..., Finland
Supervisor of Doctoral Thesis: Osmo Hakosalo, Hannes Tapani Lohi, 2010 → ..., Finland

Aarno Palotie, Supervisor of doctoral dissertation: Tiina Haljo, Aarno Palotie, 2005
Supervisor of doctoral thesis: Danny Chan, Aarno Palotie, 2005, Hong Kong
Supervisor of doctoral thesis: Denis Bronnikov, Aarno Palotie, 28.06.2005, United States
Supervisor of doctoral thesis: Lisa-Lanyi Mee, Aarno Palotie, 27.06.2005, United States
Supervisor of doctoral thesis: Gregory Oswell, Aarno Palotie, 2005, United States
Supervisor of doctoral thesis: Harri Visapää, Aarno Palotie, 07.06.2006, Finland
Co-supervisor of doctoral thesis: Päivi Tikka-Kleemola, Aarno Palotie, 15.06.2009, Finland
Supervisor of doctoral thesis: Verner Anttila, Aarno Palotie, 15.06.2010, Finland
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF OTHER SCIENTIFIC ACTIVITIES 2005-2010

CompDisGen/Kaprio

Leena Palotie
Supervision of Doctoral Thesis: Elina Siuvioahlti, Leena Palotie, 2005 → ...
Supervision of Doctoral Thesis: Jenny Ekholm, Leena Palotie, 2005
Supervision of Doctoral Thesis: Nabil Enattah, Leena Palotie, 2005 → ...
Supervision of Doctoral Thesis: Tero Ylisaukko-oja, Leena Palotie, 2005 → ...
Supervision of Doctoral Thesis: William Hennah, Leena Palotie, 2005 → ...
Supervision of doctoral thesis: Niklas Paikkasjärvi, Leena Palotie, 20.01.2006, Finland

William Hennah
The DISC1 Pathway in the Genetic Etiology of Schizophrenia, William Hennah, 2010, Finland

Janna Saarela
Supervisor of the PhD thesis: Suvi Kallio, Janna Saarela, 26.06.2009, Finland

Päivi Marjaana Saavalainen
Supervision of a PhD dissertation of Katri Haimila, Päivi Marjaana Saavalainen, 01.01.2002 → 24.04.2009, Finland
Supervision of a PhD dissertation of Lotta Koskinen, Päivi Marjaana Saavalainen, 01.01.2005 → 25.09.2009, Finland

Elisabet Einarsdottir
Genetics of celiac disease, Elisabet Einarsdottir, 2009 → ..., Finland

Marja-Riitta Taskinen
Supervision of Doctoral thesis, Marja-Riitta Taskinen, 18.05.2007, Finland
Supervision of Doctoral thesis, Marja-Riitta Taskinen, 09.10.2009, Finland

Tiilamajaja Tuomi
Supervision of doctoral thesis: Åsa Linda Carlsson, Tiilamajaja Tuomi, 1995 → ..., Finland
Supervision of doctoral thesis: Brita Liljestroem, Tiilamajaja Tuomi, 2003 → ..., Finland
Supervision of Advanced Studies: Elina Honkanen, Tiilamajaja Tuomi, 2005, Finland
Supervision of Advanced Studies: Hanna Koskela, Tiilamajaja Tuomi, 2006, Finland
Supervision of Advanced Studies: Elisa Hietamaki, Tiilamajaja Tuomi, 2008, Finland
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF OTHER SCIENTIFIC ACTIVITIES 2005-2010

CompDisGen/Kaprio

Supervisor of Advanced Studies: Sanna Alkio, Tiinamaija Tuomi, 2008, Finland
Supervisor of Advanced Studies: Linda Stoor, Tiinamaija Tuomi, 2010, Finland
Supervisor of doctoral thesis: Virve Lundgren, Tiinamaija Tuomi, 2010 → ... Finland

Prizes and awards

Jaakko Kaprio,
Elected Epidemiologist of the Year by the Finnish Epidemiological Society, Jaakko Kaprio, 2005, Finland
Doctor of Medicine h.c., Jaakko Kaprio, 2006, Denmark
First Prize Paper Presentation at 2007 meeting, Jaakko Kaprio, 2007, United Kingdom
Young Neurosurgeon -competition 2nd prize, Jaakko Kaprio, 2007, Finland
Kappa Delta Award, Orthopedic Research Society, Jaakko Kaprio, 2008, United States
Knight 1st Class, Finnish Order of the White Rose, Jaakko Kaprio, 2008, Finland
Maud Kuistila memorial award for excellence in post-graduate teaching, Jaakko Kaprio, 2008, Finland

Juha Kere,
Medix Prize 2005 for the best Finnish biomedical research paper published in 2004, Juha Kere, 2005, Finland
Distinguished Professor Award, Juha Kere, 2009, Sweden

Katarina Sara Eriikka Hannula-Jouppi,
The Endocrine Society and Pfizer, Inc. International Award for Excellence in Published Clinical Research in the Journal of Clinical Endocrinology and Metabolism 2009, Katarina Sara Eriikka Hannula-Jouppi, 2009 → ... United States

Ville Pertti Pulkkinen,
Medix Prize 2005 for the best Finnish biomedical research article, Ville Pertti Pulkkinen, 21.10.2005

Kimmo Kontula,
Invited Member of the Finnish Science Academy (Suomalainen Tiedeakatemia), Kimmo Kontula, 1994 → ... Finland
Inspector of The Nation of the Southern Finland (ESO), University of Helsinki, Kimmo Kontula, 2009 → 2010
Matti Äyräpää Award, Duodecim Society, Kimmo Kontula, 2005, Finland
Honorary Member of The Duodecim Society of Helsinki District, Kimmo Kontula, 2007 → ... Finland
Invited Member of the Finnish Society of Sciences and Letters (Suomen tiedeseura), Kimmo Kontula, 2007 → ... Finland
The Order of the White Rose in Finland, Kimmo Kontula, 2007, Finland
Honorary Member of The Nation of the Southern Finland (ESO), University of Helsinki, Kimmo Kontula, 2010
Hypertension Specialist of the European Hypertension Society, Kimmo Kontula, 2010
Teaching Person of the Year, Faculty of Medicine, University of Helsinki, Kimmo Kontula, 2010, Finland

Hannes Tapani Lohi,
Academy Research Fellowship, Hannes Tapani Lohi, 2006, Finland
Start up grant, Hannes Tapani Lohi, 2006, Finland
Academy Award for Scientific Courage, Hannes Tapani Lohi, 2007, Finland
Academy Award for scientific courage, Hannes Tapani Lohi, 01.01.2007, Finland
Award for Scientific Courage, Hannes Tapani Lohi, 2007, Finland
Canine epilepsy models, Hannes Tapani Lohi, 2008
Outstanding Young Person of Finland (TOYP), Hannes Tapani Lohi, 2009
Outstanding Young Person of the World finalist, Hannes Tapani Lohi, 2009
The Outstanding Young Person of Finland, Hannes Tapani Lohi, 2009, Finland
“Myötäkarvaan” honor recognition by the FinnExpo, Hannes Tapani Lohi, 2010, Finland
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF OTHER SCIENTIFIC ACTIVITIES 2005-2010

CompDisGen/Kaprio

The European Research Council (ERC) Starting Grant, Hannes Tapani Lohi, 2010

Elisa Nevalainen,
Outstanding poster, Elisa Nevalainen, 25.09.2010, United States

Leena Palotie,
Eric K. Fernströms Nordiska Priset, Leena Palotie, 2006, Sweden
European van Gysel Prize for Biomedical Research, Leena Palotie, 2006
Honorary Professor of the Faculty of Clinical Medicine, Cambridge University, Leena Palotie, 2008, United Kingdom
Academician of Science, Leena Palotie, 2009, Finland
The Carter Medal, Leena Palotie, 2009, United Kingdom

Janna Saarela,
2008 Kappa Delta Elisabeth Winston Lanier Award for Outstanding Orthopaedic Research, Janna Saarela, 05.03.2008, United States

Elisabet Einarsdottir,
Finnish Coeliac Society research grant, Elisabet Einarsdottir, 2010

Marja-Riitta Taskinen,
Esko A. Nikkilä Award, Marja-Riitta Taskinen, 01.01.2006 → 31.12.2011, Finland
Novartis Prize in Diabetes (Long-standing achievement), Marja-Riitta Taskinen, 01.01.2006 → 31.12.2011

Editor of research journal

Jaakko Kaprio,
Editorial Board Member: Psychiatric Genetics, Jaakko Kaprio, 01.01.1990 → ..., United States
Editor board Member: Finnish Journal of Social Medicine, Jaakko Kaprio, 01.01.1994 → ..., Finland
Associate Editor: Twin Research, Jaakko Kaprio, 01.01.1998 → ..., United Kingdom
Editorial Board Member: International Journal of Behavioral Medicine, Jaakko Kaprio, 01.01.1999 → ..., United States
Addiction Associate editor, Jaakko Kaprio, 2004 → ...
Associate Editor: Nicotine & Tobacco Research, Jaakko Kaprio, 01.01.2010 → ..., United Kingdom
Nicotine & Tobacco Research Associate editor, Jaakko Kaprio, 2010 → ...

Ulla Heidi Broms,
Social Science &amp; Medicine, Ulla Heidi Broms, 04.02.2005 → 31.12.2005, United States
European Journal of Cardiovascular Prevention and Rehabilitation, Ulla Heidi Broms, 17.05.2006 → 31.12.2006
Psychological Medicine, Ulla Heidi Broms, 19.10.2006 → 31.12.2006, United States
Tobacco Induced Diseases, Ulla Heidi Broms, 01.10.2008 → 31.12.2011, United States

Anna Keski-Rahkonen,
European Eating Disorders Review, Anna Keski-Rahkonen, 01.01.2005 → 31.12.2005
Psychiatry Research, Anna Keski-Rahkonen, 01.01.2005 → 31.12.2005

Juha Kere,
Member of editorial board: Human Genetics, Juha Kere, 2005 → ...
Member of editorial board: Human Molecular Genetics, Juha Kere, 2005 → 2010

Katarina Sara Erilikka Hannula-Jouppi,
Pediatric pulmonology, Katarina Sara Erilikka Hannula-Jouppi, 01.01.2005 → 31.12.2005

Kimmo Kontula,
Member of the Editorial Board, Annals of Medicine, Kimmo Kontula, 1989 → 2010
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE
UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF OTHER SCIENTIFIC ACTIVITIES 2005-2010

CompDisGen/Kaprio

Timo Hiltunen, Biomarkers, Timo Hiltunen, 19.01.2009 → 30.01.2009, United Kingdom
Hypertension, Timo Hiltunen, 21.05.2009 → 02.06.2009, United States
Hypertension, Timo Hiltunen, 02.04.2009 → 18.04.2009, United States


Stroke, Aarno Palotie, 2004 → 2005, United States
American Journal of Human Genetics, Aarno Palotie, 2005, United States
American Journal of Medical genetics, Aarno Palotie, 2005, United States
Annals of Neurology, Aarno Palotie, 2005
European Journal of cancer, Aarno Palotie, 2005, United Kingdom
Human Genetics, Aarno Palotie, 2005
Human Molecular Genetics, Aarno Palotie, 2005
Journal of Molecular Diagnostics, Aarno Palotie, 2005
Molecular Psychiatry, Aarno Palotie, 2005
Neurogenetics, Aarno Palotie, 2005
Stroke, Aarno Palotie, 2005, United States

Leena Palotie, Psychiatric Genetics, Leena Palotie, 1989 → 2010, United States
American Journal of Medical Genetics, Leena Palotie, 1992 → 2010, United States
Current Opinion in Genetics and Development, Leena Palotie, 2000 → 2010, United Kingdom
Gene Function &amp; Disease, Leena Palotie, 2000 → 2010, United States
Molecular Genetics and Metabolism, Leena Palotie, 2000 → 2010, United States
Annals of Human Genetics, Leena Palotie, 2008 → 2010, United States
Genes, Leena Palotie, 2009 → 2010
Trends in Genetics, Leena Palotie, 2009 → 2010

Janna Saarela, Editor: Annals of Medicine, Janna Saarela, 01.01.2008 → ...

Marja-Riitta Taskinen, Arteriosclerosis, Thrombosis and Vascular Biology, Marja-Riitta Taskinen, 01.01.2005 → 31.12.2005, United States
Diabetes, Marja-Riitta Taskinen, 01.01.2005 → 31.12.2005, United States
Diabetes Care, Marja-Riitta Taskinen, 01.01.2005 → 31.12.2005, United States
Diabetologia, Marja-Riitta Taskinen, 01.01.2005 → 31.12.2005, Germany
J Clin Endocrinol Metab, Marja-Riitta Taskinen, 01.01.2005 → 31.12.2005, United States
NMCD, Marja-Riitta Taskinen, 01.01.2005 → 31.12.2005, Italy
Obesity Research, Marja-Riitta Taskinen, 01.01.2005 → 31.12.2005, United States
Arteriosclerosis, Thrombosis and Vascular Biology, Marja-Riitta Taskinen, 01.01.2006 → 31.12.2006, United States
Diabetes, Marja-Riitta Taskinen, 01.01.2006 → 31.12.2006, United States
RC-SPECIFIC TUHAT COMPILATIONS OF OTHER SCIENTIFIC ACTIVITIES 2005-2010

CompDisGen/Kaprio

Diabetes Care, Marja-Riitta Taskinen, 01.01.2006 → 31.12.2006, United States
Diabetologia, Marja-Riitta Taskinen, 01.01.2006 → 31.12.2006
Journal of Lipid Research, Marja-Riitta Taskinen, 01.01.2006 → 31.12.2006, United States
The Journal of Clinical Endocrinology and Metabolism, Marja-Riitta Taskinen, 01.01.2006 → 31.12.2006, United States
Vascular Health and Risk Management, Marja-Riitta Taskinen, 01.01.2006 → 31.12.2006, New Zealand

Tiitamaria Tuomi,
Reviewer for Diabetes, Tiitamaria Tuomi, 2000 → ..., United States
Reviewer of Diabetes Care, Tiitamaria Tuomi, 2000 → ..., United States
Reviewer of Diabetologia, Tiitamaria Tuomi, 2000 → ...
Editor of Duodecim, Tiitamaria Tuomi, 2003 → ...

Elisabeth Ingrid Maria Widen,
European Journal of Human Genetics, Elisabeth Ingrid Maria Widen, 01.01.2006 → 31.12.2010
Journal of Clinical Investigation, Elisabeth Ingrid Maria Widen, 01.01.2006 → 31.12.2006

Peer review of manuscripts
Jaakko Kaprio,
Arteriosclerosis, thrombosis and vascular biology, Jaakko Kaprio, 01.01.2005 → 31.12.2005, United States
Behavior Genetics, Jaakko Kaprio, 01.01.2005 → 31.12.2005, United States
European Journal of Human Genetics, Jaakko Kaprio, 01.01.2005 → 31.12.2005, United Kingdom
Health Psychology, Jaakko Kaprio, 01.01.2005 → 31.12.2005, United States
International Journal of Obesity, Jaakko Kaprio, 01.01.2005 → 31.12.2005, United Kingdom
Journal of Internal Medicine, Jaakko Kaprio, 01.01.2005 → 31.12.2005, Australia
Nicotine and Tobacco Research, Jaakko Kaprio, 01.01.2005 → 31.12.2005, United Kingdom
Referee for manuscript submitted to the Scandinavian Journal of Public Health, Jaakko Kaprio, 2005
Behavior Genetics, Jaakko Kaprio, 01.01.2006 → 31.12.2006, United States
Current Directions in Psychological Science, Jaakko Kaprio, 01.01.2006 → 31.12.2006, United States
Diabetologia, Jaakko Kaprio, 01.01.2006 → 31.12.2006, United States
European Journal of Human Genetics, Jaakko Kaprio, 01.01.2006 → 31.12.2006, United Kingdom
Health Psychology, Jaakko Kaprio, 01.01.2006 → 31.12.2006, United States
Journal of Sleep Research, Jaakko Kaprio, 01.01.2006 → 31.12.2006, United Kingdom
Journal of Sleep Research, Jaakko Kaprio, 01.01.2006 → 31.12.2006
Nicotine and Tobacco research, Jaakko Kaprio, 01.01.2006 → 31.12.2006, United Kingdom
Springer Publisher (review of article for Handbook of Behavior Genetics), Jaakko Kaprio, 01.01.2006 → 31.12.2006, United Kingdom
New England Journal of Medicine, Jaakko Kaprio, 01.01.2007 → 31.12.2007, United States
BMJ, Jaakko Kaprio, 01.01.2008 → 31.12.2008, United Kingdom
COPD, Jaakko Kaprio, 01.01.2008 → 31.12.2008
European Journal of Endocrinology, Jaakko Kaprio, 01.01.2008 → 31.12.2008, United Kingdom
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF OTHER SCIENTIFIC ACTIVITIES 2005-2010

CompDisGen/Kaprio

European Spine Journal, Jaakko Kaprio, 01.01.2008 → 31.12.2008, United Kingdom
International Journal of Obesity, Jaakko Kaprio, 01.01.2008 → 31.12.2008, United Kingdom
Kinesiologia Slovenica, Jaakko Kaprio, 01.01.2008 → 31.12.2008, Slovenia
Twin Research and Human Genetics, Jaakko Kaprio, 01.01.2008 → 31.12.2008, United Kingdom
Am J Psychiatry, Jaakko Kaprio, 2010
Atherosclerosis, Thrombosis and Vascular Biology, Jaakko Kaprio, 2010
Psychological Medicine, Jaakko Kaprio, 2010
Referee for Diabetes and Metabolism, Jaakko Kaprio, 2010

Tellervo Korhonen

Health Education Research: Theory & Practice, Tellervo Korhonen, 2001 → 2005
Health Psychology, Tellervo Korhonen, 2001 → 2005
Addictive Behaviors, Tellervo Korhonen, 2005 → 2006
International Journal of Behavioral Medicine, Tellervo Korhonen, 2006 → ...
Addiction, Tellervo Korhonen, 2007 → 2009
BMC Public Health, Tellervo Korhonen, 2008 → ...
Archives of General Psychiatry, Tellervo Korhonen, 2008 → ...
Drug and Alcohol Dependence, Tellervo Korhonen, 2009 → ...
Journal of Adolescence, Tellervo Korhonen, 2009 → ...
Journal of Women's Health, Tellervo Korhonen, 2009 → ...
Annals of Medicine, Tellervo Korhonen, 2010 → ...
European Journal of Public Health, Tellervo Korhonen, 2010 → ...
Nicotine & Tobacco Research, Tellervo Korhonen, 2010 → ...

Katarina Sara Eriikka Hannula-Jouppi

GeneReviews Genetic Disease Online Reviews, Katarina Sara Eriikka Hannula-Jouppi, 2001 → ...
Pediatric Pulmonology, Katarina Sara Eriikka Hannula-Jouppi, 2005 → ...
American Journal of Medical Genetics, Katarina Sara Eriikka Hannula-Jouppi, 2006 → ...
Orphanet Journal of Rare Diseases, Katarina Sara Eriikka Hannula-Jouppi, 2006 → ...
Medical Science Monitor, Katarina Sara Eriikka Hannula-Jouppi, 2007 → ...
Pediatric Research, Katarina Sara Eriikka Hannula-Jouppi, 2007 → ...

Hannes Tapani Lohi

Genetics, Hannes Tapani Lohi, 2008
Genome Research, Hannes Tapani Lohi, 2008
Journal of Heredity, Hannes Tapani Lohi, 20.06.2008
Nature Genetics, Hannes Tapani Lohi, 2008
Veterinary Journal, Hannes Tapani Lohi, 20.08.2008
Animal Genetics, Hannes Tapani Lohi, 2009
Journal of Heredity, Hannes Tapani Lohi, 20.06.2009
Journal for Molecular Medicine, Hannes Tapani Lohi, 2010

Aarno Palotie

Acted as peer review of a manuscripts: Cell, Aarno Palotie, 2005 → 2010
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF OTHER SCIENTIFIC ACTIVITIES 2005-2010

CompDisGen/Kaprio

Peer review of manuscripts in journals: Nature Genetics, European Journal of Human Genetics, Human Molecular Genetics, American Journal of Human Genetics, Nucleic Acid Research, Aarno Palotie, 2005 → 2010

Samuli Olli Ripatti,
Reviewed manuscripts for the Alcoholism: Clinical and Experimental Research, Samuli Olli Ripatti, 2005 → 2010
Reviewed manuscripts for the Biometrical Journal, Samuli Olli Ripatti, 2005 → 2010
Reviewed manuscripts for the Biostatistics Journal, Samuli Olli Ripatti, 2005 → 2010
Reviewed manuscripts for the European Journal of Human Genetics, Samuli Olli Ripatti, 2005 → 2010
Reviewed manuscripts for the Genetic Epidemiology, Samuli Olli Ripatti, 2005 → 2010
Reviewed manuscripts for the Journal of Computational and Graphical Statistics, Samuli Olli Ripatti, 2005 → 2010
Reviewed manuscripts for the Lifetime Data Analysis Journal, Samuli Olli Ripatti, 2005 → 2010

Päivi Marjaana Saavalainen,
Reviewer for Eur J Hum Genet, Päivi Marjaana Saavalainen, 26.07.2005
Reviewer for Eur J Hum Genet, Päivi Marjaana Saavalainen, 20.03.2006
Reviewer for Tissue Antigens, Päivi Marjaana Saavalainen, 02.10.2006
Scandinavian Journal of Gastroenterology, Päivi Marjaana Saavalainen, 01.11.2006 → 30.11.2006
Reviewer for Tissue Antigens, Päivi Marjaana Saavalainen, 08.11.2007
Reviewer for J Med Genet, Päivi Marjaana Saavalainen, 09.03.2009
Reviewer for Tissue Antigens, Päivi Marjaana Saavalainen, 07.09.2009
Reviewer for Annals of Medicine, Päivi Marjaana Saavalainen, 07.10.2010
Reviewer for International Archives of Allergy and Immunology, Päivi Marjaana Saavalainen, 02.03.2010

Elisabeth Ingrid Maria Widen,
Acted as a reviewer in journal of Medical Genetics, Elisabeth Ingrid Maria Widen, 2005
Acted as a reviewer in a journal: European Journal of Human Genetics, Elisabeth Ingrid Maria Widen, 2006 → 2010
Acted as a reviewer in a journal: Scandinavian Journal of Clinical Investigation, Elisabeth Ingrid Maria Widen, 2006 → ...
Acted as a reviewer in Journal of Pediatrics, Elisabeth Ingrid Maria Widen, 2009 → ...
Acted as a reviewer in a journal; Annals of Medicine, Elisabeth Ingrid Maria Widen, 2010
Acted as a reviewer of a manuscript in a journal: American Journal of Human Genetics, Elisabeth Ingrid Maria Widen, 2010

Assessment of candidates for academic posts

Jaakko Kaprio,
Evaluation for full professorship in Community Medicine and Health Care: Dr. Richard Stevens, Jaakko Kaprio, 2006, United States
Evaluation for tenure track assistant professorship in Psychology: Danielle M Dick, Jaakko Kaprio, 2006, United States
Docentship reviewer: Tomi-Pekka Tuomainen, Jaakko Kaprio, 2007, Finland
Evaluation for Associate Professor of Harvard University: Taru Kinnunen, Jaakko Kaprio, 2007, United States
Evaluation for Associate Professor, Univ of Southern California, Jaakko Kaprio, 2007, United States
Evaluation of Senior Research Fellow-position: Dr. Grant Montgomery, Jaakko Kaprio, 2007, Australia
Evaluation for Full Professor: Alex MacGregor, Jaakko Kaprio, 2008, United Kingdom
Assessment of candidate for academic post: Docentship: Markus Jokela, Jaakko Kaprio, 2009, Finland
Evaluation for promotion to Associate Professor: Valerie Knopik, Jaakko Kaprio, 2009, United States
Professorschhip evaluation: Päivi Rautava, Jaakko Kaprio, 2009, Finland
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF OTHER SCIENTIFIC ACTIVITIES 2005-2010

CompDisGen/Kaprio

Aarno Palotie,
Expert evaluator of professorship at the Uppsala University, Aarno Palotie, 2008, Sweden

Elisabeth Ingrid Maria Widen,
Assessment of candidate for academic post: Adjunct professor/Docentship: Sirpa Kivirikko, Elisabeth Ingrid Maria Widen, 2005, Finland

Membership or other role in review committee

Jaakko Kaprio,
Review committee member: EUPHA, Jaakko Kaprio, 01.01.2008 → 31.12.2010, Portugal
Grant evaluations, Jaakko Kaprio, 2009, United Kingdom
Pre-examiner for PhD, Jaakko Kaprio, 2009
Pre-examiner for PhD thesis, Jaakko Kaprio, 2009
Pre-examiner for PhD, Jaakko Kaprio, 2010
Review of grant applications, Jaakko Kaprio, 2010
Three year grant evaluations, Jaakko Kaprio, 2010 → …

Tellervo Korhonen,
12th Annual Conference SRNT Europe, Tellervo Korhonen, 01.05.2010 → 10.06.2010

Aarno Palotie,
Member of International Review Committee of LUMC, University of Leiden, Aarno Palotie, 2005, Netherlands

Samuli Olli Ripatti,
Member in review committee: ZonMW, Samuli Olli Ripatti, 2007 → …
ERC Advance Grant referee, Samuli Olli Ripatti, 2009 → …, Belgium
ERC starting grant referee, Samuli Olli Ripatti, 2009 → …, Belgium

Membership or other role in research network

Jaakko Kaprio,
Elected Member: Finnish Academy for Science and Letters, Jaakko Kaprio, 2009 → …, Finland

Leena Palotie,
Human Genome Organization: President, Leena Palotie, 2005 → 2007

Samuli Olli Ripatti,
Member in Nordic Center of Excellence for Disease Genetics: Harmonization of control database, Samuli Olli-Ripatti, 2007 → 2010
Network in AcademiaP3G, Working Group 2, Samuli Olli-Ripatti, 2008 → …
Project manager in Biostatistics group (GENESTAT) in EU FP6 coordinated action PHOEBE, Samuli Olli-Ripatti, 2008 → 2009
Steering Group Member in EU FP7 project ENGAGE, cardiovascular risk factors, statistical genetics, Samuli Olli-Ripatti, 2008 → …

Janna Saarela,
Nordic MS Genetics Network: Finnish representative, Janna Saarela, 01.01.2004 → …
National Public Health Institute: Member of DNA Steering group, Janna Saarela, 01.01.2006 → 31.12.2008, Finland
Finnish representative in the International MS Genetics consortium (IMSGC), Janna Saarela, 01.01.2008 → …
Biocenter Finland ‘Genome-wide methods’ network: Member, Janna Saarela, 01.01.2009 → …, Finland

Tiinamaja Tuomi,
Board member of HBGS, Tiinamaja Tuomi, 2003 → …, Finland
Member of DIAGRAM (Diabetes Genetics Replication and Meta-Analysis), Tiinamaja Tuomi, 2008 → …
Steering committee member of Transmed, Tiinamaja Tuomi, 2010 → …, Finland

12
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF OTHER SCIENTIFIC ACTIVITIES 2005-2010

CompDisGen/Kaprio

Membership or other role in national/international committee, council, board
Jaakko Kaprio,

Finnish Epidemiological Society, Jaakko Kaprio, 2000 → ..., Finland
Expert Member in the Academy of Finland, Jaakko Kaprio, 01.01.2002 → 31.12.2007, Finland
Agence National de Recherche, Jaakko Kaprio, 01.01.2005 → 31.12.2005, France
Cim, Jaakko Kaprio, 01.01.2005 → 31.12.2005, Finland
Finnish Epidemiological Society, Jaakko Kaprio, 01.01.2005 → 31.12.2005, Finland
International Congress on Behavior Medicine, Jaakko Kaprio, 01.01.2005 → 31.12.2005, United States
International Congress on Behavior Medicine, Jaakko Kaprio, 01.01.2005 → 31.12.2005, United States
International Congress on Behavior Medicine, Jaakko Kaprio, 01.01.2005 → 31.12.2005
International Society for Twin Studies, Jaakko Kaprio, 01.01.2005 → 31.12.2005, Australia
International Society for Twin Studies, Jaakko Kaprio, 01.01.2005 → 31.12.2005
International Society for Twin Studies, President, Jaakko Kaprio, 2005 → 2007, Australia
President for the International Society for Twin Studies, Jaakko Kaprio, 2005 → 2007, Australia
Society for Research on Nicotine and Tobacco, Jaakko Kaprio, 01.01.2005 → 31.12.2005, United States
Society for Research on Nicotine and Tobacco, Jaakko Kaprio, 01.01.2005 → 31.12.2005
Swedish Research Council, Jaakko Kaprio, 01.01.2005 → 31.12.2005
European research advisory board, Jaakko Kaprio, 01.01.2006 → 31.12.2006, France
Finnish Epidemiological Society, Jaakko Kaprio, 01.01.2006 → 31.12.2006, Finland
International Society for Twin Studies, Jaakko Kaprio, 01.01.2006 → 31.12.2006, Australia
Käyttäytymislääketieteen jaos, Sosiaalilääketieteen yhdistys 2006, Jaakko Kaprio, 01.01.2006 → 31.12.2006, Finland
Paolo Foundation, Jaakko Kaprio, 01.01.2006 → 31.12.2008, Finland
European research advisory board, Jaakko Kaprio, 01.01.2007 → 31.12.2007, France
Finnish Epidemiological Society, Jaakko Kaprio, 01.01.2007 → 31.12.2007, Finland
International Society for Twin Studies, Jaakko Kaprio, 01.01.2007 → 31.12.2007, Australia
Käyttäytymislääketieteen jaos, Sosiaalilääketieteen yhdistys 2007, Jaakko Kaprio, 01.01.2007 → 31.12.2007, Finland
Center for Gender Medicine at Karolinska Institute, Jaakko Kaprio, 01.01.2008 → 31.12.2008, Sweden
Finnish Epidemiological Society, Jaakko Kaprio, 01.01.2008 → 31.12.2008, Finland
French National Research Agency (AnR) programme, "GENOPAT: From the gene to the physiopathology, Jaakko Kaprio, 01.01.2008 → 31.12.2008, France
Helsinki University Hospital Fund (EVO) evaluation board, Jaakko Kaprio, 2008 → ...
Society for Research on Nicotine and Tobacco, Jaakko Kaprio, 01.01.2008 → 31.12.2008, Italy
Academy of Finland Medical Research Council member, Jaakko Kaprio, 2010 → 2012, Finland
Finnish Cancer Foundation governing board member, Jaakko Kaprio, 2010 → 2012, Finland
Ulla Heidi Broms,
Sosiaalilääketieteen yhdistys, Käyttäytymislääketieteen jaos, Ulla Heidi Broms, 01.01.2005 → 31.12.2005, Finland
Finnish Epidemiological Society, Ulla Heidi Broms, 01.04.2008 → 31.12.2010, Finland
Anna Keski-Rahkonen,
Academy for Eating Disorders: Conference Committee, Anna Keski-Rahkonen, 01.01.2005 → 31.12.2005, United States
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF OTHER SCIENTIFIC ACTIVITIES 2005-2010

CompDisGen/Kaprio


Tellervo Korhonen,

International Society of Behavioral Medicine, Tellervo Korhonen, 2008 → 2011, Finland

Current Care Working Group, Tellervo Korhonen, 2010 → ..., Finland

Suoma Eeva Matilda Saarni,

Suomen Lihavuustutkijat ry, Suoma Eeva Matilda Saarni, 01.01.2004 → 31.12.2005, Finland

Suomen Lääketieteellinen Filosofian Seura, Suoma Eeva Matilda Saarni, 01.04.2005 → 31.12.2010, Finland

Suomen Lihavuustutkijat ry, Suoma Eeva Matilda Saarni, 01.01.2008 → 31.12.2008, Finland

Suomen Lääketieteellinen Filosofian Seura ry, Suoma Eeva Matilda Saarni, 01.01.2008 → 31.12.2008, Finland

Kaisu Keskitalo,

ETS:n aistinvaraisen tutkimuksen jaosto, Kaisu Keskitalo, 2008, Finland

ETS:n hallitus, Kaisu Keskitalo, 2008, Finland

Juha Kere,

Board of Directors, Finnish Cancer Foundation and Finnish Foundation for Cancer Research, Juha Kere, 1999 → 2007, Finland

Scientific Advisory Board, The Centre for Applied Genomics, The Hospital for Sick Children, Juha Kere, 1999 → ..., Canada

Steering Committee, Graduate School of Computational Biology (ComBi), University of Helsinki, Juha Kere, 1999 → ..., Finland

Biocentrum Helsinki, Juha Kere, 2000 → 2006, Finland

Medical Board, Sigrid Jusélius Foundation, Juha Kere, 2000 → ..., Finland

Scientific Advisor, Finnish Genome Center, Juha Kere, 2001 → 2007, Finland

Board of Directors, Finnish Genome Center, Juha Kere, 2002 → 2007, Finland

Co-founder and Board of Directors, GeneOS Ltd., Juha Kere, 2002 → 2007, Finland

Scientific Advisory Board, Spanish Genotyping Network (SGN), Juha Kere, 2003 → ..., Spain

Nobel Assembly (for the Prize in Physiology or Medicine), Juha Kere, 2004 → ..., Sweden

Nobel Committee (for the Prize in Physiology or Medicine), Juha Kere, 2004 → ..., Sweden

Biocentrum Helsinki, Juha Kere, 2007 → 2010, Finland

European Molecular Biology Organization (EMBO), Juha Kere, 2007

Member of advisory committee for Assistant Professor of Medical Genetics, Juha Kere, 2007, Sweden

Member of advisory committee for Strategic Professor on genome integrity, Juha Kere, 2007, Sweden

Cluster of Life Science Advisory Council (CLAC), Juha Kere, 2008 → ..., Japan

Kimmo Kontula,

Member of The Finnish Medical Society Duodecim, Kimmo Kontula, 1986 → ..., Finland

Member of the Scientific Board - The Jalmari and Rauha Ahtokas Foundation, Kimmo Kontula, 1989 → 2005, Finland

Member of Steering Committee - MD PhD Program of the Faculty of Medicine, University of Helsinki, Kimmo Kontula, 1994 → 2006, Finland

Suomalainen Tiedeakatemia, Kimmo Kontula, 1994 → ..., Finland

Member of the Committee for the Medical Nomenclature, Duodecim, Kimmo Kontula, 1995 → ..., Finland

Member of the Board of Directors, The Paavo Nurmi Foundation, Kimmo Kontula, 1996 → ..., Finland

Chairman of the Board of Directors, The Finnish Cultural Foundation, Kimmo Kontula, 2001 → 2006, Finland

Puheenjohtaja, Suomen Kulttuurirahaston hallitus, Kimmo Kontula, 2001 → 2006, Finland

Vice Chairman of the Board for the Basic Medical Examination, Kimmo Kontula, 2002 → 2008, Finland

Member of the Council, The Finnish Foundation for Medical Research, Kimmo Kontula, 2004 → ..., Finland
CompDisGen/Kaprio

Chairman of the Board of Directors of The Finnish Medical Society Duodecim, Kimmo Kontula, 2005 → 2007, Finland
Member of the Board of Directors, The Finnish National Theatre, Kimmo Kontula, 2005 → ..., Finland
Member of the Council, The Finnish Cultural Foundation, Kimmo Kontula, 2006 → ..., Finland
Chairman of the Executive Group of the Research Programs, Faculty of Medicine, University of Helsinki, Kimmo Kontula, 2007 → 2009, Finland
Chairman of the Faculty Administrative Committee, Faculty of Medicine, University of Helsinki, Kimmo Kontula, 2007 → 2009, Finland
Chairman of the Regional Board for Specialist Education, Faculty of Medicine, University of Helsinki, Kimmo Kontula, 2007 → 2009, Finland
Dean and Chairman of the Faculty Administrative Committee, Faculty of Medicine, University of Helsinki, Kimmo Kontula, 2007 → 2009, Finland
Johkunnan puheenjohtaja, Kimmo Kontula, 2007 → 2009, Finland
Member of the Board of Directors, The Institute for Molecular Medicine Finland (FIMM), Kimmo Kontula, 2007 → 2010, Finland
Member of the Collegium of the University of Helsinki, Kimmo Kontula, 2007 → 2009, Finland
Chairman of the Board of Directors, National Library for Health Sciences, Kimmo Kontula, 2008 → 2009, Finland
Member of the Executive Group, Helsinki University Central Hospital, Kimmo Kontula, 2008 → 2009, Finland
Chairman of the Board of Palmenia Centre for Continuing Education, University of Helsinki, Kimmo Kontula, 2010 → ..., Finland
Chairman of the Board of UniSport, University of Helsinki, Kimmo Kontula, 2010 → ..., Finland
Chairman, Board of Directors, FIMM, Kimmo Kontula, 2010 → ...
Member of the Surveillance Group, Helsinki University Central Hospital, Kimmo Kontula, 2010 → ..., Finland

Hannes Tapani Lohi ,
American Society of Human Genetics, Hannes Tapani Lohi, 2008
Biocentrum Helsinki, Hannes Tapani Lohi, 01.01.2008 → 31.12.2010, Finland
Finnish Professor Association, Hannes Tapani Lohi, 2008
Member of Biocentrum Helsinki, Hannes Tapani Lohi, 2008 → 2013, Finland
Member of the Editorial Scientific Board of the Journal of Epithelial Biology and Pharmacology (JEBP), Hannes Tapani Lohi, 2008 → ..., Finland
Member of the Nordic Center of Excellence in Disease Genetics, Hannes Tapani Lohi, 2008 → ..., Finland
Member of the Steering Committee of the EU-funded LUPA project for canine genomics, Hannes Tapani Lohi, 2008 → 2012
Nordic Center of Excellence in Disease Genetics, Hannes Tapani Lohi, 01.08.2008
Nordic Center of Excellence in Disease Genetics, Hannes Tapani Lohi, 01.01.2008 → 31.12.2008
The Steering Committee of the EU-funded LUPA project for dog genomics, Hannes Tapani Lohi, 01.01.2008 → 31.12.2012
Member of the "Genomic selection" Follow-up Committee for the Ministry of Agriculture and Forestry, Hannes Tapani Lohi, 2009 → ..., Finland
Dog Health Research Fund, Hannes Tapani Lohi, 01.01.2010 → 31.12.2012, Finland
Member of the Board of the Research Programs Unit, Faculty of Medicine, Hannes Tapani Lohi, 2010 → ...
Member of the Committee of the Research and Postgraduate Education Planning, Faculty of Veterinary Medicine, Hannes Tapani Lohi, 2010 → ...
Member of the GSPB-graduate school evaluation panel, Hannes Tapani Lohi, 2010 → ..., Finland
Vice Member of the Board of the Institute of Biotechnology, Hannes Tapani Lohi, 2010 → ..., Finland

Aarno Palotie ,
European Scientific Science Foundation Functional Genome Programme, Aarno Palotie, 2004 → 2005
GenomEUtwin Steering Group, Aarno Palotie, 2004 → 2005
Helsinki Biomedical Graduate School, Aarno Palotie, 2004 → 2005, Finland
Helsinki Computational Biology Graduate School, Aarno Palotie, 2004 → 2005, Finland
RC-SPECIFIC TUHAT COMPILED COMMISSIONS OF OTHER SCIENTIFIC ACTIVITIES 2005-2010

CompDisGen/Kaprio

Mehiläisen tieteellinen neuvottelukunta, Aarno Palotie, 2004 → 2005, Finland
Member of Study Section, Assays and Methods Development, NIH, Aarno Palotie, 2004 → 2005, United States
NIH Study Section Biotechnical Task Committee, Aarno Palotie, 2004 → 2005, United States
Nordic Committee of Education, Aarno Palotie, 2004 → 2005
Chair of Evaluation Panel, Academy of Finland, Aarno Palotie, 2005, Finland
Chair of Evaluation Panel, The Belgian Science Policy (BELSPO), Aarno Palotie, 2005, Belgium
Member of Evaluation Panel, Wallenberg Consortium North, technology platforms, Aarno Palotie, 2005, Sweden
Member of Evaluation Panel, The Swedish Research Council for Medicine, Aarno Palotie, 2006, Sweden
Board member of Biocentrum Helsinki, Aarno Palotie, 2007 → 2008, Finland
Evaluation Panel, Uppsala University: Quality and Renewal Evaluation, Aarno Palotie, 2007 → ..., Sweden
Member of Evaluation Panel, Wallenberg Consortium North, technology platforms, Aarno Palotie, 2008, Sweden
Member of the search committee for virology at the Welcome Trust Sanger Institute, Aarno Palotie, 2008, United Kingdom

Leena Palotie

European Molecular Biology Organization (EMBO), Leena Palotie, 1991 → 2010, Germany
Finnish Academy of Sciences and Letters, Leena Palotie, 01.01.1993 → 11.03.2010, Finland
Scientific Advisory Board, Center for Molecular Medicine, Karolinska Institutet, Leena Palotie, 1996 → 2010, Sweden
European Academy of Sciences (Academiae Europaeae), Leena Palotie, 1999 → 2010, Belgium
Scientific Advisory Board of the Genome Research Programme, Foundation for Strategic Research, Leena Palotie, 1999 → 2010, Sweden
Board of the Genetics Prize of the Peter Gruber Foundation, Leena Palotie, 01.01.2001 → 31.12.2009, United States
Member of the Scientific Advisory Board of British Biobanks, Leena Palotie, 2001 → 2010, United Kingdom
The Scientific Advisory Board of Biobanks, Leena Palotie, 2001 → 2010, Netherlands
Member of the Scientific Advisory Board of the Shanghai Genome Center, Leena Palotie, 2002 → 2010
Societas Scientiarum Fennica, Leena Palotie, 2002 → 2010, Finland
Institutional Advisory Board of VIB, Ghent, Leena Palotie, 01.01.2003 → 31.12.2009, Belgium
Member of VIB Departmental Evaluation Board, University of Antwerp, Leena Palotie, 2003 → 2010, Belgium
Board of Publicly Funded Population Projects in Genomics (P3G), Leena Palotie, 01.01.2004 → 11.03.2010, Canada
European Society of Human Genetics, Leena Palotie, 01.01.2004 → 31.12.2005, Austria
Helsingin yliopisto, tutkimusneuvosto, Leena Palotie, 01.01.2004 → 31.12.2006, Finland
Populations and Public Health Strategy Committee, Wellcome Trust: Chair, Leena Palotie, 2004 → 2010, United Kingdom
Board of European Research Council (ERC), Leena Palotie, 01.01.2005 → 31.03.2010
Committee member of Nordisk Forskningskomitéen, Novo Nordisk Foundation, Leena Palotie, 2005
European Academy of Sciences (Academiae Europaeae), Leena Palotie, 01.01.2005 → 31.12.2005, Belgium
European Molecular Biology Organization (EMBO), Leena Palotie, 01.01.2005 → 31.12.2005, Germany
Evaluation Board Member, Uppsala University, Leena Palotie, 2005, Sweden
HUGO - The Human Genome Organisation, Leena Palotie, 01.01.2005 → 31.12.2007, United Kingdom
Member of Board of Directors of P3G, Leena Palotie, 2005
Member of EMBO Publications & Electronic Information Committee, Leena Palotie, 2005
MolPAGE Scientific Advisory Board, Leena Palotie, 2005 → 2010, United Kingdom
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF OTHER SCIENTIFIC ACTIVITIES 2005-2010

CompDisGen/Kaprio

Scientific Advisory Board of European Research Council, ERC, Leena Palotie, 2005 → 2010, Belgium

The consequences, opportunities and challenges of modern biotechnology for Europe (Bio4EU), Leena Palotie, 01.01.2005 → 31.12.2008, Belgium

Fondation Louis Jeantet, Leena Palotie, 01.01.2006 → 11.03.2010, Switzerland

Foreign Associate Member in the Institute of Medicine of the National Academies, Leena Palotie, 01.01.2006 → 11.03.2010, United States

International Advisory Panel (IAP) - Government of Catalonia - Catalan Pact for Research, Leena Palotie, 01.01.2007 → 11.03.2010

Future Trends Forum (FTF), Bankinter Foundation of Innovation, Leena Palotie, 01.01.2008 → 31.12.2010, Spain

Member, Board of Danish National Research Foundation, Leena Palotie, 2009 → 2010, Denmark

Päivi Marjaana Saavalainen

Helsingin Biolääketieteellinen Tuhjakoulu, Päivi Marjaana Saavalainen, 01.05.2005 → 31.10.2005

Biocentrum Helsinki, Päivi Marjaana Saavalainen, 01.01.2008 → 31.12.2010, Finland

Helsinki Graduate School in Biotechnology and Molecular Biology, Päivi Marjaana Saavalainen, 01.01.2008 → 31.12.2010, Finland

Päivi Marjaana Saavalainen

Research Program Unit, Päivi Marjaana Saavalainen, 01.06.2010 → ...

Marja-Riitta Taskinen

Claude Bernard Award Nomination Committee, Marja-Riitta Taskinen, 01.01.2005 → 31.12.2005

European Atherosclerosis Society (EAS), Marja-Riitta Taskinen, 01.01.2005 → 31.12.2005

International Atherosclerosis Society, Marja-Riitta Taskinen, 01.01.2005 → 31.12.2005

Metabolic Syndrome Institute, Marja-Riitta Taskinen, 01.01.2005 → 31.12.2005

European Atherosclerosis Society (EAS), Marja-Riitta Taskinen, 01.01.2006 → 2008

International Atherosclerosis Society (IAS), Marja-Riitta Taskinen, 01.01.2006 → 31.12.2006

EAS/ESC Guideline Committee on Management of dyslipidemias, Marja-Riitta Taskinen, 2009 → ...

Tiinamaija Tuomi

Board Member of Suomen Diabetestutkijat ja Diabetologit ry, Tiinamaija Tuomi, 1999 → ..., Finland

Suomen Diabetestutkijat ja Diabetologit ry, Tiinamaija Tuomi, 1999 → ..., Finland

Membership or other role in public Finnish or international organization

Jaakko Kaprio

Acted as reviewer of the Academy of Finland applications, Jaakko Kaprio, 2002 → 2007, Finland

Department Head and Chair of Steering Board: Dept of Public Health, Helsinki, Jaakko Kaprio, 2004 → 2008, Finland

HY Yhteiskunnallisen vuorovaikutuksen työryhmän jäsen, Jaakko Kaprio, 01.01.2004 → 31.12.2006, Finland

Lääk. tdk tutkimusneuvoston jäsen, Jaakko Kaprio, 01.01.2004 → 31.12.2006, Finland

Lääket. tdk tutkimusneuvoston jäsen, Jaakko Kaprio, 01.01.2004 → 31.12.2006, Finland

Lääket. tdk tutkimusneuvoston jäsen, Jaakko Kaprio, 01.01.2004 → 31.12.2006, Finland

Vaalikollegion jäsen, Jaakko Kaprio, 01.01.2004 → 31.12.2006, Finland

Vaalikollegion jäsen, Jaakko Kaprio, 01.01.2004 → 31.12.2006, Finland

Vaalikollegion jäsen, Helsingin yleispoli, Jaakko Kaprio, 01.01.2004 → 31.12.2006, Finland

HY Yhteiskunnallisen vuorovaikutuksen työryhmän jäsen, Jaakko Kaprio, 01.01.2004 → 31.12.2005, Finland

HY Yhteiskunnallisen vuorovaikutuksen työryhmän jäsen, Jaakko Kaprio, 01.01.2005 → 31.12.2005, Finland

Lääk. tdk tutkimusneuvoston jäsen, Jaakko Kaprio, 01.01.2005 → 31.12.2005, Finland

Vaalikollegion jäsen, Jaakko Kaprio, 01.01.2005 → 31.12.2005, Finland

Lääk. tdk tutkimusneuvoston jäsen, Jaakko Kaprio, 01.01.2006 → 31.12.2006, Finland

Vaalikollegion jäsen, Helsingin yleispoli, Jaakko Kaprio, 01.01.2006 → 31.12.2006, Finland
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF OTHER SCIENTIFIC ACTIVITIES 2005-2010

CompDisGen/Kaprio

Lääket. tdk tutkimusneuvoston jäsen, Jaakko Kaprio, 01.01.2007 → 31.12.2007, Finland
HY, yliopistoudunut tutkimuksen projektiryhmän, Jaakko Kaprio, 01.01.2008 → 31.12.2010, Finland
International Society for Twin Studies, Past-President, Jaakko Kaprio, 01.01.2008 → 31.12.2010, Australia
Lääket. tdk tutkimusneuvoston jäsen, Jaakko Kaprio, 01.01.2008 → 31.12.2008, Finland

Ulla Heidi Broms,
Asiantuntijajäsenten Valtakunnallinen Tupaakka ja Terveyspäivän suunnitteluomikunta, Filha ry., KTL, Ulla Heidi Broms, 01.10.2005 → 12.12.2006, Finland
H-gin yliopisto, Kansanterveystieteen laitoki, johtoryhmän jäsen, Ulla Heidi Broms, 01.01.2005 → 20.03.2005, Finland
HY, Kansanterveystieteen laitoksen johtoryhmän jäsen, Ulla Heidi Broms, 01.01.2006 → 31.12.2006

Tellervo Korhonen,

Kimmo Kontula,
Lääketieteentin sanastolautakunta, jäsen, Kimmo Kontula, 1995 → …, Finland
Paavo Nurmen Säätiön hallitus, Kimmo Kontula, 1996 → …
Kääpä hoito -johtoryhmän jäsen, Kimmo Kontula, 2005 → 2007, Finland
Kustannus Oy Duodecimin hallitus, Kimmo Kontula, 2006 → 2008, Finland

Hannes Tapani Lohi,
Ministry of Social and Health Affairs, Hannes Tapani Lohi, 19.08.2006 → 01.08.2008, Finland
Ministry of Social and Health Affairs, Hannes Tapani Lohi, 19.08.2006 → 01.08.2008, Finland
Health Club of the Finnish hound association, Hannes Tapani Lohi, 01.01.2007 → 31.12.2011, Finland
MTT Agrifood Research Finland, Hannes Tapani Lohi, 01.06.2009 → 31.12.2011, Finland

Katrina Annikki Tira,
Invalidilitto, Avustajakoiratyöryhmän, Katrina Annikki Tira, 01.01.2005 → 31.12.2005, Finland

Leena Palotie,
Orion Board Member, Leena Palotie, 01.01.2004 → 11.03.2010, Finland
Faculty of Medicine, Lund University, Leena Palotie, 01.01.2005 → 31.12.2010, Sweden
Novo Nordisk Fonden, scientific board, Leena Palotie, 01.01.2005 → 11.03.2010, Denmark
UNIK International Expert Panel, Minister of Science, Technology and Innovation, Leena Palotie, 01.01.2008 → 11.03.2010, Denmark

Marja-Riitta Taskinen,
Liikuntatieteident jaost, Marja-Riitta Taskinen, 01.08.2007 → 31.12.2011, Finland

Tiilamaija Tuomi,
Chair of the Medical Advisory Board of the Finnish Diabetes Association, Tiilamaija Tuomi, 2005 → …, Finland

Membership or other role of body in private company/organisation

Jaakko Kaprio,
Monikkoperheet ry:n asiantuntija "kummi", 10v juhlassa sain kunniavirin., Jaakko Kaprio, 01.01.2005 → 31.12.2005, Finland
Monikkoperheet ry:n asiantuntija "kummi", 10v juhlassa sain kunniavirin., Jaakko Kaprio, 01.01.2005 → 31.12.2005, Finland
Monikkoperheet ry:n asiantuntija, Jaakko Kaprio, 01.01.2006 → 31.12.2006, Finland

Ulla Heidi Broms,
Sosiaalilääketieteiden yhdistys ry, Käyttäytymisääketieteiden jaost, Ulla Heidi Broms, 01.01.2005 → 31.12.2006
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF OTHER SCIENTIFIC ACTIVITIES 2005-2010

Kimmo Kontula
Eteläsuomalainen osakunta, inspehtori, Kimmo Kontula, 01.03.2000 → 28.02.2010, Finland
Hallintoneuvoston jäsen, Kimmo Kontula, 2004 → ..., Finland
Member of the Board of Culminatum Innovation Ltd., Kimmo Kontula, 2010 → ..., Finland

Jaakko Kaprio
Interview in Ilta-Sanomat newspaper, Jaakko Kaprio, 04.07.2006, Finland
Interview in Mediuutiset (in English: Medical News), Jaakko Kaprio, 04.07.2006, Finland
Press Release in HGM2006 Meeting, Jaakko Kaprio, 31.05.2006, Finland

Jukka Tapani Lehtonen
Suomi-Madagaskar seura ry:n Madagaskar-iltta, Luonnontieteellisellä keskusmusolla, Jukka Tapani Lehtonen, 05.03.2003 → 31.12.2011, Belgium

Hannes Tapani Lohi
Newspaper article in Helsingin Sanomat, Hannes Tapani Lohi, 02.2005, Finland
Interview in Koirat magazine, Hannes Tapani Lohi, 2007, Finland
Newspaper interview in Helsingin Sanomat, Hannes Tapani Lohi, 05.12.2007, Finland
Interview in Kemia magazine, Hannes Tapani Lohi, 05.2008, Finland
Newspaper interview in Tieda Magazine, Hannes Tapani Lohi, 05.10.2008, Finland
Interview in Seura Magazine, Hannes Tapani Lohi, 17.09.2009, Finland
Newspaper interview in Savon Sanomat, Hannes Tapani Lohi, 25.04.2009, Finland
Article in Ajokoiramies, Hannes Tapani Lohi, 05.2010, Finland
Newspaper interview in Metsästäjä Magazine, Hannes Tapani Lohi, 30.09.2008, Finland
Newspaper interview in Kaleva, Hannes Tapani Lohi, 29.09.2008, Finland
Interview in Demodex: Geenit: koirien geenitutkimus auttaa rodunjalostusta - ja ihmistä!, Hannes Tapani Lohi, 2009, Finland
Interview in Springeri Magazine, Hannes Tapani Lohi, 09.2009, Finland
Newspaper interview in Savon Sanomat, Hannes Tapani Lohi, 25.04.2009, Finland
Interview in Ajokoiramies, Hannes Tapani Lohi, 05.2010, Finland
Newspaper interview in Kauppa-lehti, Hannes Tapani Lohi, 31.01.2010, Finland
Newspaper interview in Helsingin Sanomat, Hannes Tapani Lohi, 31.12.2010, Finland
Newspaper interview in Helsingin Sanomat Kuukausiliite (monthly supplement), Hannes Tapani Lohi, 2010, Finland
Presentation for international press, Hannes Tapani Lohi, 29.11.2010, Finland

Leena Palotie
Interview in BiotechScandinavia Magazine, Leena Palotie, 04.2005
Interview in Diabetes magazine, Leena Palotie, 04.2005, Finland
Interview in Discover Magazine, Leena Palotie, 04.2005, United States
Interview in Europa Magazine, Leena Palotie, 05.2005, Finland
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF OTHER SCIENTIFIC ACTIVITIES 2005-2010

CompDisGen/Kaprio

Interview in “Avain, Nyckeln” Magazine, Leena Palotie, 2006, Finland
Interview in “Itä-Savo” newspaper, Leena Palotie, 14.06.2006, Finland
Interview in “Made in Holland” Magazine, Leena Palotie, 04.2006, Netherlands
Interview in “Tiede” Magazine - In English “Science” Magazine, Leena Palotie, 2006, Finland
Interview in “Yliopistopaino” Magazine, Leena Palotie, 01.2006, Finland
Interview in Finnfacts Magazine, Leena Palotie, 2006, Finland
Interview in Mediutiset Magazine, Leena Palotie, 17.11.2006, Finland
Interview in Orion Magazine, Leena Palotie, 2006, Finland
Interview in “Helsingin Sanomat, kuukausiliite”, Leena Palotie, 04.2007, Finland
Interview in “Hyvä Terveys” Magazine (in English “Good Health” Magazine, Leena Palotie, 01.2007, Finland
Interview in “PRIMA” Magazine, Leena Palotie, 2007, Finland
Interview in Galenos magazine (Orion Pharma), Leena Palotie, 24.08.2007, Finland
Interview in HUSARI Magazine, Leena Palotie, 2007, Finland
Interview in Nordicum, Scandinavian Business Magazine, Leena Palotie, 05.2007
Interview in Oulu Magazine, Leena Palotie, 2007, Finland
Interview in Reader’s Digest, Leena Palotie, 12.2007, Finland
Interview in Universitat Helsingiensis, Leena Palotie, 2007, Finland
Interview in Diabetes magazine, Leena Palotie, 08.2008, Finland
Interview in Promo magazine, Leena Palotie, 02.2008, Finland
Interview in Newspaper “Karjalainen”, Leena Palotie, 08.02.2009, Finland

Samuli Olli Ripatti

Interview in “Ajassa” magazine “Ambassador of genes”, personal profile of Samuli Ripatti, Samuli Olli Ripatti, 09.2010
Interview in Tiede magazine (“Science”): “Where do Finns come from?”., Samuli Olli Ripatti, 09.2010
Samuli Ripatti’s Interview in Helsingin Sanomat about the origin on Finns and 1000 genomes project, Samuli Olli Ripatti, 17.03.2010

Tiinamaja Tuomi

Newspaper interview in Helsingin Sanomat, Tiinamaja Tuomi, 2005, Finland
Newspaper interview in Helsingin lääkärilehti, Tiinamaja Tuomi, 2005, Finland
Interview in HyväTerveys Magazine, Tiinamaja Tuomi, 08.2005, Finland
Interview in Diabetes Magazine, Tiinamaja Tuomi, 08.2006, Finland
Interview in Diabetes Magazine (Finnish Diabetes Association), Tiinamaja Tuomi, 2010, Finland

Participation in radio programme

Jaakko Kaprio

Interview in Yleisradio (National Radio channel), Jaakko Kaprio, 04.07.2006, Finland

Tellervo Korhonen

BBC Radio Program: Health Check, Tellervo Korhonen, 21.05.2007, United Kingdom
Tupakoinnin lopettaminen on vaikeampaa kuin luullaan, Tellervo Korhonen, 11.03.2010, Sweden

Kaisu Keskitalo

MTV3 News, Kaisu Keskitalo, 07.03.2008
Yle News, Kaisu Keskitalo, 07.03.2008
Yle X3M Radio, Kaisu Keskitalo, 06.03.2008
Yle I Radio Ykkösaamu, Kaisu Keskitalo, 11.03.2008
CompDisGen/Kaprio

Katariina Sara Eriikka Hannula-Jouppi,
The axon guidance receptor gene ROBO1 is a candidate gene for developmental dyslexia. PLOS Genetics 2005, Katariina Sara Eriikka Hannula-Jouppi, 2005, Finland

Elina Salmela,
Haastattelu YLE:n radiouutisissa, Elina Salmela, 24.10.2008

Jukka Tapani Lehtonen,
Yle radio yksi, ohjelma: Kasvotroikka kaukomaille: Dodon vihreä saari - Madagaskar, Jukka Tapani Lehtonen, 20.03.2007 → 31.12.2011, Belgium

Hannes Tapani Lohi,
Radio interview on Reseptori, Hannes Tapani Lohi, 19.03.2010, Finland

Leena Palotie,
Interview in National Radio YLE 1, Leena Palotie, 30.10.2009, Finland

Samuli Olli Ripatti,
Samuli Ripatti’s interview in Finnish National Radio1, Reseptori Science Program about "Finnish genes", Samuli Olli Ripatti, 07.07.2010

Päivi Marjana Saavalainen,
Radio interview, Päivi Marjana Saavalainen, 04.03.2010, Finland

Elisabeth Ingrid Maria Widen,
Interview in Finnish National Radio 1, Reseptori Science Program, Elisabeth Ingrid Maria Widen, 04.2010, Finland

Participation in TV programme

Katariina Sara Eriikka Hannula-Jouppi,
The axon guidance receptor gene ROBO1 is a candidate gene for developmental dyslexia. PLOS Genetics 2005, Katariina Sara Eriikka Hannula-Jouppi, 2005, Finland

Ville Peltti Pulkkinnen,
Interview on YLE Prisma TV program, Ville Peltti Pulkkinnen, 02.09.2010

Elina Salmela,
Haastattelu YLE:n TV-uutisissa, Elina Salmela, 24.10.2008

Kimmo Kontula,
Television interview: Kenen verenpaine hoitoon?, Kimmo Kontula, 24.08.2006, Finland

Hannes Tapani Lohi,
Television interview on MOT, Hannes Tapani Lohi, 02.2007, Finland

Television interview on MTV 3, Hannes Tapani Lohi, 04.2007, Finland

Television interview on TV 2 (YLE channel 2), Hannes Tapani Lohi, 08.2007, Finland

Television interview on Teema, Hannes Tapani Lohi, 2009, Finland

Aarno Palotie,
Interview in Prisma Studio - Finnish National TV - YLE TV 1, Aarno Palotie, 20.11.2010

Leena Palotie,
Lukuisia radio-, TV- ja lehdistästantuleja, muun muassa kaksi Heurekan yleisökuventaa sekä esiintyminen Suuret Suomalaiset- ja Maan Mannin televiisio-ohjelmissa, Leena Palotie, 02.06.2006, Finland

Lukuisia radio-, TV- ja lehdistästantuleja ja kolumneja, mm. Arto Nyberg -ohjelma, Leena Palotie, 30.12.2007, Finland

TV program: Aamuysäntä, Leena Palotie, 06.12.2009, Finland

TV program: 45 minuuttia, Leena Palotie, 09.12.2009, Finland

21
INTERNATIONAL EVALUATION OF RESEARCH AND DOCTORAL TRAINING AT THE UNIVERSITY OF HELSINKI

RC-SPECIFIC TUHAT COMPILATIONS OF OTHER SCIENTIFIC ACTIVITIES 2005-2010

CompDisGen/Kaprio

Samuli Olli Ripatti,
Interview in seven o’clock news in MTV3 Finnish National TV, Samuli Olli Ripatti, 16.03.2010
TV program ”Puoli seitsemän”, Samuli Olli Ripatti, 14.04.2010

Janna Saarela,
Kaupalliset geenitsestit, Janna Saarela, 12.11.2009, Finland

Tiinamaija Tuomi,
Television interview on Prisma Studio, Tiinamaija Tuomi, 01.01.2003 → 31.12.2011, Finland

Elisabeth Ingrid Maria Widen,
TV-program Arto Nyberg in YLE TV1, Elisabeth Ingrid Maria Widen, 18.04.2010

Participation in interview for web based media

Tellervo Korhonen,
Smoking behaviour as a predictor for depression, Tellervo Korhonen, 29.05.2007

Leena Palotie,
Interview on SciVee, Leena Palotie, 2008, United States

Päivi Marjaana Saavalainen,
Press release, Päivi Marjaana Saavalainen, 01.03.2010
Research Group: Kaprio J

Basic statistics

- Number of publications (P): 890
- Number of citations (TCS): 12,104
- Number of citations per publication (MCS): 13.76
- Percentage of uncited publications: 19%
- Field-normalized number of citations per publication (MNCS): 2.17
- Field-normalized average journal impact (MNJS): 1.94
- Field-normalized proportion highly cited publications (top 10%): 2.21
- Internal coverage: .89

Trend analyses

Performance (MNCS) by collaboration type